

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssspta1202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * * * * Welcome to STN International * * * * * * * * * * * *

| | | |
|------|----|---|
| NEWS | 1 | Web Page for STN Seminar Schedule - N. America |
| NEWS | 2 | CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present |
| NEWS | 3 | NOV 26 MARPAT enhanced with FSORT command |
| NEWS | 4 | NOV 26 CHEMSAFE now available on STN Easy |
| NEWS | 5 | NOV 26 Two new SET commands increase convenience of STN searching |
| NEWS | 6 | DEC 01 ChemPort single article sales feature unavailable |
| NEWS | 7 | DEC 12 GBFULL now offers single source for full-text coverage of complete UK patent families |
| NEWS | 8 | DEC 17 Fifty-one pharmaceutical ingredients added to PS |
| NEWS | 9 | JAN 06 The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo |
| NEWS | 10 | JAN 07 WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data |
| NEWS | 11 | FEB 02 Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATEM |
| NEWS | 12 | FEB 02 GENBANE enhanced with SET PLURALS and SET SPELLING |
| NEWS | 13 | FEB 06 Patent sequence location (PSL) data added to USGENE |

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 14:35:20 ON 09 FEB 2009

=> file reg
COST IN U.S. DOLLARS

SINCE FILE TOTAL
ENTRY SESSION

FULL ESTIMATED COST

0.22

0.22

FILE 'REGISTRY' ENTERED AT 14:35:34 ON 09 FEB 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 6 FEB 2009 HIGHEST RN 1101988-13-9
 DICTIONARY FILE UPDATES: 6 FEB 2009 HIGHEST RN 1101988-13-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
 Uploading C:\Program Files\Stnexp\Queries\10088814a.str



```

chain nodes :
11 18 19 21 27 28
ring nodes :
1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17 20 22 23 24 25 26
chain bonds :
2-28 3-27 7-11 11-12 15-18 18-19 19-20 19-21
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17 20-22 20-26 22-23 23-24 24-25 25-26
exact/norm bonds :
2-28 3-27 7-11 11-12 15-18 18-19 19-21
exact bonds :
19-20
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17 20-22 20-26 22-23 23-24 24-25 25-26
  
```

10/ 088,814

isolated ring systems :
containing 1 : 12 : 20 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
20:Atom 21:CLASS 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:CLASS 28:CLASS

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 14:35:54 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 46 TO ITERATE

100.0% PROCESSED 46 ITERATIONS

22 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 514 TO 1326

PROJECTED ANSWERS: 159 TO 721

L2 22 SEA SSS SAM L1

=> s 11 full

FULL SEARCH INITIATED 14:36:00 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 729 TO ITERATE

100.0% PROCESSED 729 ITERATIONS

428 ANSWERS

SEARCH TIME: 00.00.01

L3 428 SEA SSS FUL L1

```
=> file caplus
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                                ENTRY        SESSION
FULL ESTIMATED COST          185.88       186.10
```

FILE 'CAPLUS' ENTERED AT 14:36:06 ON 09 FEB 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Feb 2009 VOL 150 ISS 7
FILE LAST UPDATED: 8 Feb 2009 (20090208/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s 13
L4          21 L3
```

```
=> d 14 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 21 ANSWERS - CONTINUE? Y/(N):y
```

L4 ANSWER 1 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1008461 CAPLUS
DOCUMENT NUMBER: 149:462315
TITLE: Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs
AUTHOR(S): Gascoigne, Karen E.; Taylor, Stephen S.
CORPORATE SOURCE: Faculty of Life Sciences, University of Manchester,
Manchester, M13 9PT, UK
SOURCE: Cancer Cell (2008), 14(2), 111-122
CODEN: CCAECI; ISSN: 1535-6108
PUBLISHER: Cell Press
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Drugs targeting the mitotic spindle are used extensively during chemotherapy, but surprisingly, little is known about how they kill tumor cells. This is largely because many of the population-based approaches are indirect and lead to vague and confusing interpretations. Here, we use a high-throughput automated time-lapse light microscopy approach to


systematically analyze over 10,000 single cells from 15 cell lines in response to three different classes of antimitotic drug. We show that the variation in cell behavior is far greater than previously recognized, with cells within any given line exhibiting multiple fates. We present data supporting a model wherein cell fate is dictated by two competing networks, one involving caspase activation, the other protecting cyclin B1 from degradation

IT 331771-20-1, ZM447439

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs)

RN 331771-20-1 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:919061 CAPLUS

DOCUMENT NUMBER: 149:282640

TITLE: ZM 447439 inhibition of aurora kinase induces Hep2 cancer cell apoptosis in three-dimensional culture

AUTHOR(S): Long, Zi-Jie; Xu, Jie; Yan, Min; Zhang, Jian-Gang; Guan, Zhong; Xu, Da-Zhi; Wang, Xian-Ren; Yao, Jine; Zheng, Fei-Meng; Chu, Guo-Liang; Cao, Jun-Xia; Zeng, Yi-Xin; Liu, Quentin

CORPORATE SOURCE: State Key Laboratory of Oncology in South China; Cancer Center, Sun Yat-sen University, Guangzhou, Peop. Rep. China

SOURCE: Cell Cycle (2008), 7(10), 1473-1479
 CODEN: CCEYAS; ISSN: 1538-4101

PUBLISHER: Landes Bioscience

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Mitotic Aurora kinases are essential for accurate chromosome segregation during cell division. Forced overexpression of Aurora kinase results in centrosome amplification and multipolar spindles, causing aneuploidy, a hallmark of cancer. ZM447439 (ZM), an Aurora selective ATP-competitive inhibitor, interferes with the spindle integrity checkpoint and chromosome segregation. Here, we showed that inhibition of Aurora kinase by ZM


reduced histone H3 phosphorylation at Ser10 in Hep2 carcinoma cells. Multipolar spindles were induced in these ZM-treated G2/M-arrested cells with accumulation of 4N/8N DNA, similar to cells with genetically suppressed Aurora-B. Cells subsequently underwent apoptosis, as assessed by cleavage of critical apoptotic associated protein PARP. Hep2 cells formed a tumor-like cell mass in 3-dimensional matrix culture; inhibition of Aurora kinase by ZM either destructed the preformed cell mass or prevented its formation, by inducing apoptotic cell death as stained for cleaved caspase-3. Lastly, ZM inhibition of Aurora kinase was potently in association with decrease of Akt phosphorylation at Ser473 and its substrates GSK3 α/β phosphorylation at Ser21 and Ser9. Together, we demonstrated that Aurora kinase served as a potential mol. target of ZM for more selective therapeutic cancer treatment.

IT 331771-20-1, ZM447439

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ZM-447439 inhibition of aurora kinase induces Hep2 cancer cell apoptosis in three-dimensional culture)

RN 331771-20-1 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:722686 CAPLUS

DOCUMENT NUMBER: 149:462285

TITLE: Molecular Basis of Drug Resistance in Aurora Kinases

AUTHOR(S): Girdler, Fiona; Sessa, Fabio; Patercoli, Simona;

Villa, Fabrizio; Musacchio, Andrea; Taylor, Stephen

CORPORATE SOURCE: Faculty of Life Sciences, University of Manchester, Manchester, M13 9PT, UK

SOURCE: Chemistry & Biology (Cambridge, MA, United States) (2008), 15(6), 552-562

CODEN: CBOLE2; ISSN: 1074-5521

PUBLISHER: Cell Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Summary: Aurora kinases have emerged as potential targets in cancer therapy, and several drugs are currently undergoing preclin. and clin. validation. Whether clin. resistance to these drugs can arise is unclear.


The authors exploited a hypermutagenic cancer cell line to select mutations conferring resistance to a well-studied Aurora inhibitor, ZM447439. All resistant clones contained dominant point mutations in Aurora B. Three mutations map to residues in the ATP-binding pocket that are distinct from the "gatekeeper" residue. The mutants retain wild-type catalytic activity and were resistant to all of the Aurora inhibitors tested. The studies predict that drug-resistant Aurora B mutants are likely to arise during clin. treatment. Furthermore, because the plasticity of the ATP-binding pocket renders Aurora B insensitive to multiple inhibitors, the observations indicate that the drug-resistant Aurora B mutants should be exploited as novel drug targets.

IT 331771-20-1, ZM447439

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mol. basis of drug resistance in Aurora kinases)

RN 331771-20-1 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




IT 331771-20-1D, ZM447439, complex with Aurora B kinase

RL: PRP (Properties)
(mol. basis of drug resistance in Aurora kinases)

RN 331771-20-1 CAPLUS


CN Benzamide, N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2008:581441 CAPLUS
 DOCUMENT NUMBER: 149:524704
 TITLE: Molecular docking/dynamics studies of Aurora A kinase inhibitors
 AUTHOR(S): Talele, Tanaji T.; McLaughlin, Mark L.
 CORPORATE SOURCE: Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, St. John's University, Jamaica, NY, 11439, USA
 SOURCE: Journal of Molecular Graphics & Modelling (2008), 26(8), 1213-1222
 CODEN: JMGMFI; ISSN: 1093-3263
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The binding modes of a known 1,4,5,6-tetrahydropyrido[3,4-c]pyrazole, quinazoline, pyrimidine and indolinone series of Aurora A kinase inhibitors have been studied using mol. docking and mol. dynamics (MD) simulations. Crystallog. bound compound 8 was precisely predicted by our docking procedure as evident from 0.43 Å root mean square (rms) deviations. In addition compound 25 (AZ-68) has been successfully cross-docked within the Aurora A kinase active site, which was pre-organized for inhibitor 8. We found four key sites (A: solvent-exposed front pocket, B: hinge region, C: selectivity pocket and D: solvent-exposed phosphate binding region) of the Aurora A kinase contributing toward the binding of these compds. We suggest that the small hydrophobic substituents at C-6 position of pyrrolopyrazole nucleus (in compds. 1-8); C-6 and C-7 positions of the quinazoline moiety (in compds. 9-23); C-2 position of the quinazoline and C-4 position of the pyrimidine (in compound 25) could be more effective and selective through increased hydrophobic contacts and selectivity pocket interactions with these modifications of Aurora A kinase inhibitors. Five representative complexes were subjected to 1000 ps of MD simulation to determine the stability of the predicted binding conformations. The low value of the root mean square deviations (ranging from 0.725 to 1.820 Å) between the starting complex structure and the energy minimized final average complex structure suggests that the Glide Extra Precision (XP) derived docked complexes are in a state of near equilibrium. The structure-based drug design strategy described in this study will be highly useful for the development of new inhibitors with high potency and


IT selectivity.
 IT 331771-20-1
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
 PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (mol. docking/dynamics studies of Aurora A kinase inhibitors)
 RN 331771-20-1 CAPLUS
 CN Benzamide, N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-
 quinazolinyl]amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2008:263784 CAPLUS
 DOCUMENT NUMBER: 148:420044
 TITLE: Discovery of Selective Aminothiazole Aurora Kinase Inhibitors
 AUTHOR(S): Andersen, Carsten B.; Wan, Yongqin; Chang, Jae W.; Riggs, Blake; Lee, Christian; Liu, Yi; Sessa, Fabio; Villa, Fabrizio; Kwiatkowski, Nicholas; Suzuki, Melissa; Nallan, Laxman; Heald, Rebecca; Musacchio, Andrea; Gray, Nathanael S.
 CORPORATE SOURCE: Department of Biological Chemistry, Genomics Institute, The Novartis Research Foundation, San Diego, CA, 92121, USA
 SOURCE: ACS Chemical Biology (2008), 3(3), 180-192
 CODEN: ACBCT; ISSN: 1554-8929
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Aurora family kinases regulate important events during mitosis including centrosome maturation and separation, mitotic spindle assembly, and chromosome segregation. Misregulation of Aurora kinases due to genetic amplification and protein overexpression results in aneuploidy and may contribute to tumorigenesis. Here we report the discovery of new small mol. aminothiazole inhibitors of Aurora kinases with exceptional kinase selectivity and report a 1.7 Å cocrystal structure with the Aurora B:INCENP complex from *Xenopus laevis*. The compds. recapitulate the hallmarks of Aurora kinase inhibition, including decreased histone H3 serine 10 phosphorylation, failure to complete cytokinesis, and endoreduplication.

IT 331771-20-1, ZM 447439
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)
 (selective aminothiazole inhibitors can inhibit Aurora kinase-mediated
 cellular phosphorylation)
 RN 331771-20-1 CAPLUS
 CN Benzanide, N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-
 quinazolinyl]amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2008:181335 CAPLUS
 DOCUMENT NUMBER: 148:440441
 TITLE: Small-molecule inhibition of Aurora kinases triggers spindle checkpoint-independent apoptosis in cancer cells
 AUTHOR(S): Sun, Lei; Li, Dengwen; Dong, Xin; Yu, Haiyang; Dong, Jin-Tang; Zhang, Chuanmao; Lu, Xianyu; Zhou, Jun
 CORPORATE SOURCE: Department of Genetics and Cell Biology, College of Life Sciences, Nankai University, Tianjin, 300071, Peop. Rep. China
 SOURCE: Biochemical Pharmacology (2008), 75(5), 1027-1034
 CODEN: BCPA6; ISSN: 0006-2952
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Aurora kinases are key regulators of mitotic progression and have also been implicated in tumorigenesis. Small mols. that inhibit Aurora kinases have shown impressive anticancer activity in preclin. studies and are currently under clin. evaluation. In this study, our data show that suppression of Aurora activity with a specific inhibitor prevents the proliferation of breast cancer cells. Mol. modeling studies indicate that the Aurora inhibitor suppresses Aurora activity by competitive displacement of ATP. Mechanistically, the Aurora inhibitor causes the accumulation of multinucleated cells, leading to profound apoptosis in the absence of caspase-3 activity. Further studies show that the sensitivity of cancer cells to the Aurora inhibitor is independent of the spindle checkpoint. In addition, the Aurora inhibitor acts synergistically with the vinca alkaloids but not with the taxanes in inhibiting cell proliferation and inducing apoptosis. These results suggest that Aurora inhibitors


might be effective in spindle checkpoint-defective cancer cells and a combination of Aurora inhibitors with the vinca alkaloids is a promising approach for cancer chemotherapy.

IT 331770-21-9

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(BADM; small-mol. inhibition of Aurora kinases triggers spindle checkpoint-independent apoptosis in cancer cells)

RN 331770-21-9 CAPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:101545 CAPLUS

DOCUMENT NUMBER: 148:325215

TITLE: The pharmacophore hypothesis of novel inhibitors for Aurora A kinase

AUTHOR(S): Wang, Xiao-Jian; Chen, Ya-Dong; Yang, Qian; You, Qi-Dong

CORPORATE SOURCE: Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, Jiangsu, 210009, Peop. Rep. China

SOURCE: Chinese Journal of Chemistry (2007), 25(12), 1911-1918 CODEN: CJOCEV; ISSN: 1001-604X


PUBLISHER: Shanghai Institute of Organic Chemistry

DOCUMENT TYPE: Journal


LANGUAGE: English

AB A three-dimensional pharmacophore model was developed from a series of inhibitors of Aurora A kinase to discover new potent anti-cancer agents using the HypoGen module in the Catalyst software. The pharmacophore model was developed based on the structure of 20 currently available inhibitors, which were carefully selected from the literature. The best hypothesis (Hypo 1) was defined by four features: one hydrogen-bond donor and three hydrophobic points, with the best correlation coefficient of 0.909, the lowest rms deviation of 1.563, and the highest cost difference of 99.075. The Hypo 1 was then validated by a test set consisting of 24 compds. and by a cross-validation of 95% confidence level through randomizing the data using the CatScramble program, which suggested that a predictive pharmacophore model had been successfully obtained.

IT 331770-21-9 331771-20-1
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)
 (inhibitor; pharmacophore hypothesis of novel inhibitors for Aurora A
 kinase)
 RN 331770-21-9 CAPLUS
 CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (CA INDEX
 NAME)



RN 331771-20-1 CAPLUS
 CN Benzamide, N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-
 quinazolinyl)amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 20071654903 CAPLUS
 DOCUMENT NUMBER: 147:250097
 TITLE: A novel treatment strategy targeting Aurora kinases in
 acute myelogenous leukemia
 Ikezoe, Takayuki; Yang, Jing; Nishioka, Chie; Tasaka,
 Taizo; Taniguchi, Ayuko; Kuwayama, Yoshio; Komatsu,
 Naoki; Bandobashi, Kentaro; Togitani, Kazuto;

AUTHOR(S):

CORPORATE SOURCE: Koeffler, H. Phillip; Taguchi, Hirokuni
 Department of Hematology and Respiratory Medicine,
 Kochi University, Nankoku, Kochi, Japan
 SOURCE: Molecular Cancer Therapeutics (2007), 6(6), 1851-1857
 CODEN: MCTOCE; ISSN: 1535-7163
 PUBLISHER: American Association for Cancer Research
 DOCUMENT TYPE: Journal
 LANGUAGE: English


AB The Aurora kinases play an important role in chromosome alignment, segregation, and cytokinesis during mitosis. Aberrant expression of these kinases occurs in solid tumors and is associated with aneuploidy and carcinogenesis. We found in this study that Aurora kinase A and B were aberrantly expressed in a variety of types of human leukemia cell lines ($n = 15$, e.g., PALL-1, PALL-2, HL-60, NB4, MV4-11, etc.), as well as freshly isolated leukemia cells from individuals with acute myelogenous leukemia ($n = 44$) compared with bone marrow mononuclear cells from healthy volunteers ($n = 11$), as measured by real-time PCR. ZM447439 is a novel selective Aurora kinase inhibitor. The compound induced growth inhibition, caused accumulation of cells with 4N/8N DNA content, and mediated apoptosis of human leukemia cells as measured by thymidine uptake, cell cycle anal., and annexin V staining, resp. Especially profound growth inhibition occurred with the PALL-1 and PALL-2 cells, which possess wild-type p53 gene. In contrast, ZM447439 did not inhibit clonogenic growth of myeloid committed stem cells harvested from healthy normal volunteers. Taken together, inhibition of Aurora kinases may be a promising treatment strategy for individuals with leukemia.

IT 331771-20-1, ZM447439

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia)

RN 331771-20-1 CAPLUS

CN Benzanide, N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:25086 CAPLUS

DOCUMENT NUMBER: 146:134907

TITLE: Mechanisms of mitotic cell death induced by

AUTHOR(S): Vogel, Celia; Hager, Christian; Bastians, Holger
 CORPORATE SOURCE: Institute for Molecular Biology and Tumor Research,
 Philipps University of Marburg, Marburg, Germany
 Cancer Research (2006), Volume Date 2007, 67(1),
 339-345


CODEN: CNREAA; ISSN: 0008-5472
 PUBLISHER: American Association for Cancer Research
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The novel concept of anticancer treatment termed "G2 checkpoint abrogation" aims to target p53-deficient tumor cells and is currently explored in clin. trials. The anticancer drug UCN-01 is used to abrogate a DNA damage-induced G2 cell cycle arrest leading to mitotic entry and subsequent cell death, which is poorly defined as "mitotic cell death" or "mitotic catastrophe.". We show here that UCN-01 treatment results in a mitotic arrest that requires an active mitotic spindle checkpoint, involving the function of Mad2, Bub1, BubR1, Mps1, Aurora B, and survivin. During the mitotic arrest, hallmark parameters of the mitochondria-associated apoptosis pathway become activated. Interestingly, this apoptotic response required the spindle checkpoint protein Mad2, suggesting a proapoptotic function for Mad2. However, although survivin and Aurora B are also required for the mitotic arrest, both proteins are part of an antiapoptotic pathway that restrains the UCN-01-induced apoptosis by promoting hyperphosphorylation of Bcl-2 and by inhibiting the activation of Bax. Consequently, inhibition of the antiapoptotic pathway by genetic ablation of survivin or by pharmacol. inhibitors of Aurora B or cyclin-dependent kinase 1 lead to a significant enhancement of apoptosis and therefore act synergistically with UCN-01. Thus, by defining the mechanism of cell death on G2 checkpoint abrogation we show a highly improved strategy for an anticancer treatment by the combined use of UCN-01 with abrogators of the survivin/Aurora B-dependent antiapoptotic pathway that retains the selectivity for p53-defective cancer cells.

IT 331771-20-1, ZM447439
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (mechanisms of mitotic cell death induced by chemotherapy-mediated G2
 checkpoint abrogation)

RN 331771-20-1 CAPLUS

CN Benzanide, N-[4-[(6-methoxy-7-(3-(4-morpholinyl)propoxy)-4-
 quinazolinyl]amino]phenyl]- (CA INDEX NAME)




REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:1085923 CAPLUS
DOCUMENT NUMBER: 146:434348
TITLE: Validating Aurora B as an anti-cancer drug target
AUTHOR(S): Girdler, Fiona; Gascoigne, Karen E.; Eyers, Patrick A.; Hartmuth, Sonya; Crafter, Claire; Foote, Kevin M.; Keen, Nicholas J.; Taylor, Stephen S.
CORPORATE SOURCE: Faculty of Life Sciences, University of Manchester, Manchester, M13 9PT, UK
SOURCE: Journal of Cell Science (2006), 119(17), 3664-3675
CODEN: JNC5A1; ISSN: 0021-9533
PUBLISHER: Company of Biologists Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English


AB The Aurora kinases, a family of mitotic regulators, have received much attention as potential targets for novel anti-cancer therapeutics. Several Aurora kinase inhibitors have been described including ZM447439, which prevents chromosome alignment, spindle checkpoint function and cytokinesis. Subsequently, ZM447439-treated cells exit mitosis without dividing and lose viability. Because ZM447439 inhibits both Aurora A and B, we set out to determine which phenotypes are due to inhibition of which kinase. Using mol. genetic approaches, we show that inhibition of Aurora B kinase activity phenocopies ZM447439. Furthermore, a novel ZM compound, which is 100 times more selective for Aurora B over Aurora A *in vitro*, induces identical phenotypes. Importantly, inhibition of Aurora B kinase activity induces a penetrant anti-proliferative phenotype, indicating that Aurora B is an attractive anti-cancer drug target. Using mol. genetic and chemical-genetic approaches, we also probe the role of Aurora A kinase activity. We show that simultaneous repression of Aurora A plus induction of a catalytic mutant induces a monopolar phenotype. Consistently, another novel ZM-related inhibitor, which is 20 times as potent against Aurora A compared with ZM447439, induces a monopolar phenotype. Expression of a drug-resistant Aurora A mutant reverts this phenotype, demonstrating that Aurora A kinase activity is required for spindle bipolarity in human cells. Because small mol.-mediated inhibition of Aurora A and Aurora B yields distinct phenotypes, our observations indicate that the Auroras may present two avenues for anti-cancer drug discovery.

IT 331771-20-1, ZM447439
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(validating Aurora B as an anti-cancer drug target)
RN 331771-20-1 CAPLUS
CN Benzanide, N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2006:695015 CAPLUS
 DOCUMENT NUMBER: 145:327648
 TITLE: Accurate Prediction of the Relative Potencies of Members of a Series of Kinase Inhibitors Using Molecular Docking and MM-GBSA Scoring
 AUTHOR(S): Lyne, Paul D.; Lamb, Michelle L.; Saeh, Jamal C.
 CORPORATE SOURCE: Cancer Discovery, AstraZeneca R & D Boston, Waltham, MA, 02451, USA
 SOURCE: Journal of Medicinal Chemistry (2006), 49(16), 4805-4808
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The ability of mol. docking, using the program Glide and an MM-GBSA postdocking scoring protocol, to correctly rank a number of congeneric kinase inhibitors was assessed. The approach was successful for the cases considered and suggests that this may be useful for the design of inhibitors in the lead optimization phase of drug discovery.
 IT 331770-21-9 331771-20-1
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (accurate prediction of relative potencies of kinase inhibitors using mol. docking and MM-GBSA scoring)
 RN 331770-21-9 CAPLUS
 CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)aminophenyl]- (CA INDEX NAME)



RN 331771-20-1 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT:

23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 20061331187 CAPLUS

DOCUMENT NUMBER: 144:387654

TITLE: Aurora B is required for mitotic chromatin-induced phosphorylation of Op18/Stathmin

AUTHOR(S): Gadea, Bedrick B.; Ruderman, Joan V.

CORPORATE SOURCE: Department of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA

SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2006), 103(12), 4493-4498

PUBLISHER: National Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Oncoprotein 18/Stathmin (Op18) is a microtubule-destabilizing protein that is inhibited by phosphorylation in response to many types of signals. During mitosis, phosphorylation of Op18 by cdc2 is necessary but not


sufficient for Op18 inhibition. The presence of mitotic chromosomes is addnl. required and involves phosphorylation of Ser-16 in Xenopus Op18 (and/or Ser-63 in human). Given that Ser-16 is an excellent Aurora A (Aur-A) kinase consensus phosphorylation site and the Aurora kinase inhibitor ZM447439 (ZM) blocks phosphorylation in the activation loop of Aur-A, we asked whether either Aur-A or Aurora B (Aur-B) might regulate Op18. We find that ZM blocks the ability of mitotic chromatin to induce Op18 hyperphosphorylation in Xenopus egg exts. Depletion of Aur-B, but not Aur-A, blocks hyperphosphorylation of Op18, and chromatin assembled in the absence of Aur-B fails to induce hyperphosphorylation. These results suggest that Aur-B, which concs. at centromeres of metaphase chromosomes, contributes to localized regulation of Op18 during the process of spindle assembly.

IT 331771-20-1, ZM447439

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Aurora B is required for mitotic chromatin-induced phosphorylation of Op18/Stathmin)

RN 331771-20-1 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:87918 CAPLUS

DOCUMENT NUMBER: 144:324127

TITLE: SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors

AUTHOR(S): Heron, Nicola M.; Anderson, Malcolm; Blowers, David P.; Breed, Jason; Eden, Jonathan M.; Green, Stephen; Hill, George B.; Johnson, Trevor; Jung, Frederic H.; McMiken, Helen H. J.; Mortlock, Andrew A.; Pannifer, Andrew D.; Paupit, Richard A.; Pink, Jennifer; Roberts, Nicola J.; Rowsell, Sian

CORPORATE SOURCE: AstraZeneca, Mereside, Cheshire, Macclesfield, SK10 4TG, UK

SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(5), 1320-1323

CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal
 LANGUAGE: English

AB A novel series of 5-aminopyrimidinyl quinazolines has been developed from anilino-quinazoline 1, which was identified in a high throughput screen for Aurora A. Introduction of the pyrimidine ring and optimization of the substituents both on this ring and at the C7 position of the quinazoline led to the discovery of compds. that are highly specific Aurora kinase inhibitors. Co-crystallization of one of these inhibitors with a fragment of Aurora A shows the importance of the benzamido group in achieving selectivity.


IT 331770-21-9 331771-20-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors)


RN 331770-21-9 CAPLUS

CN Benzanide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)



RN 331771-20-1 CAPLUS

CN Benzanide, N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:614536 CAPLUS
 DOCUMENT NUMBER: 143:115392
 TITLE: Preparation of conjugated small molecules for diagnostic and therapeutic use
 INVENTOR(S): Grotzfeld, Robert M.; Milanov, Zdravko V.; Patel, Hitesh K.; Lai, Andiliy G.; Mehta, Shamal A.; Lockhart, David J.
 PATENT ASSIGNEE(S): Ambit Biosciences Corp., USA
 SOURCE: U.S. Pat. Appl. Publ., 63 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| US 20050153371 | A1 | 20050714 | US 2005-31638 | 20050107 |
| AU 2005204428 | A1 | 20050728 | AU 2005-204428 | 20050107 |
| CA 2551495 | A1 | 20050728 | CA 2005-2551495 | 20050107 |
| WO 2005067644 | A2 | 20050728 | WO 2005-US56 | 20050107 |
| WO 2005067644 | A3 | 20051013 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HD, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1711825 | A2 | 20061018 | EP 2005-705221 | 20050107 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS | | | | |
| JP 2007521338 | T | 20070802 | JP 2006-549423 | 20050107 |
| PRIORITY APPLN. INFO.: | | | US 2004-535173P | P 20040107 |
| | | | US 2004-557941P | P 20040330 |
| | | | WO 2005-US456 | W 20050107 |

OTHER SOURCE(S): CASREACT 143:115392
 GI



AB Provided herein are linker compds. and conjugates that include the linker compds. In one embodiment, the linker compds. comprise 2 or 3 residues of 6-aminohexanoic acid and optionally 7-10 residues of polyethyleneglycol (PEG). The linker compds. are useful in forming conjugates with one or more components useful in biopharmaceutical or bioanal. applications. In particular, the biopharmaceutically useful compds. are kinase inhibitors. The conjugates described herein have utility in a variety of diagnostic, separation, and therapeutic applications. Thus, I was prepared from SB 202190, PEG-azide and the biotin-linker compound

IT 857892-01-4P

RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of conjugated biotins for diagnostic and therapeutic use)

RN 857892-01-4 CAPLUS


CN 1H-Thieno[3,4-d]imidazole-4-pentanamide,
hexahydro-N-[42-[4-[[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-
quinazolinyl]amino]phenyl]amino]carbonyl]phenyl]-6,13-dioxo-
17,20,23,26,29,32,35,38-octaaza-7,14,41-triazadotetracont-1-yl]-2-oxo-,
(3aS,4S,6aR)- (CA INDEX NAME)



Absolute stereochemistry.

PAGE 1-B



PAGE 2-B





L4 ANSWER 15 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:429874 CAPLUS
 DOCUMENT NUMBER: 144:145392
 TITLE: The Ipl1/aurora kinase family: Methods of inhibition
 and functional analysis in mammalian cells
 Ditchfield, Claire; Keen, Nicholas; Taylor, Stephen S.
 School of Biological Sciences, University of
 Manchester, Manchester, UK
 AUTHOR(S):
 CORPORATE SOURCE:

SOURCE: Methods in Molecular Biology (Totowa, NJ, United States) (2005), 296(Cell Cycle Control), 371-381
 CODEN: MMBIED; ISSN: 1064-3745

PUBLISHER: Humana Press Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English


AB The Ipl1/Aurora family of protein kinases are required for accurate chromosome segregation. Because members of this family are often overexpressed in human tumors, they have recently received much attention, both from the academic community and the pharmaceutical industry. Indeed, two small mol. Aurora kinase inhibitors have recently been described. In this chapter, we describe several methods for investigating the function of the Aurora kinases, focusing on Aurora B. We describe the use of the small-mol. inhibitor ZM447439, RNA interference, and overexpression of a catalytic mutant. All of these methods have proved useful in studying Aurora B as well as validating it as a potential anticancer drug target. However, while all three methods are useful for probing the function of Aurora B, each has inherent advantages and disadvantages. Furthermore, because the mechanism underlying the inhibition is different in each case, caution must be taken when interpreting the data.

IT 331771-20-1, ZM447439

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (for inhibitor studies of Aurora kinase; methods for inhibition and functional anal. of Ipl1/aurora kinase family in mammalian cells)

RN 331771-20-1 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:220855 CAPLUS
 DOCUMENT NUMBER: 143:301206
 TITLE: Aurora kinase inhibitor ZM447439 blocks chromosome-induced spindle assembly, the completion of chromosome condensation, and the establishment of the spindle integrity checkpoint in Xenopus egg extracts
 Gadea, Bedrick B.; Ruderman, Joan V.
 Department of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA

AUTHOR(S):
 CORPORATE SOURCE:

SOURCE: Molecular Biology of the Cell (2005), 16(3), 1305-1318
 CODEN: MBCEEV; ISSN: 1059-1524
 PUBLISHER: American Society for Cell Biology
 DOCUMENT TYPE: Journal
 LANGUAGE: English


AB The Aurora family kinases contribute to accurate progression through several mitotic events. ZM447439 ("ZM"), the first Aurora family kinase inhibitor to be developed and characterized, was previously found to interfere with the mitotic spindle integrity checkpoint and chromosome segregation. Here, we have used exts. of Xenopus eggs, which normally proceed through the early embryonic cell cycles in the absence of functional checkpoints, to distinguish between ZM's effects on the basic cell cycle machinery and its effects on checkpoints. ZM clearly had no effect on either the kinetics or amplitude in the oscillations of activity of several key cell cycle regulators. It did, however, have striking effects on chromosome morphol. In the presence of ZM, chromosome condensation began on schedule but then failed to progress properly; instead, the chromosomes underwent premature decondensation during mid-mitosis. ZM strongly interfered with mitotic spindle assembly by inhibiting the formation of microtubules that are nucleated/stabilized by chromatin. By contrast, ZM had little effect on the assembly of microtubules by centrosomes at the spindle poles. Finally, under conditions where the spindle integrity checkpoint was exptl. induced, ZM blocked the establishment, but not the maintenance, of the checkpoint, at a point upstream of the checkpoint protein Mad2. These results show that Aurora kinase activity is required to ensure the maintenance of condensed chromosomes, the generation of chromosome-induced spindle microtubules, and activation of the spindle integrity checkpoint.

IT 331771-20-1, ZM447439

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Aurora kinase inhibitor ZM447439 blocks chromosome-induced spindle assembly, the completion of chromosome condensation, and the establishment of spindle integrity checkpoint in Xenopus egg exts.)

RN 331771-20-1 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 80 THERE ARE 80 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:29195 CAPLUS

DOCUMENT NUMBER: 142:127561
 TITLE: Use of aurora kinase inhibitors for reducing the resistance of cancer cells to mitotic spindle assembly inhibitors
 INVENTOR(S): Anand, Shubha; Venkitaraman, Ashok
 PATENT ASSIGNEE(S): Cambridge University Technical Services Ltd., UK
 SOURCE: PCT Int. Appl., 38 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2005002571 | A1 | 20050113 | WO 2003-GB2862 | 20030703 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2531142 | A1 | 20050113 | CA 2003-2531142 | 20030703 |
| AU 2003304266 | A1 | 20050121 | AU 2003-304266 | 20030703 |
| US 20060178318 | A1 | 20060810 | US 2006-563042 | 20060313 |

PRIORITY APPLN. INFO.:


AB The invention discloses the use of anticancer agents that inhibit mitotic spindle assembly in target cells, including taxanes such as paclitaxel, and in particular to methods and means for predicting and/or reducing the resistance of cancer cells to such agents. Over-expression of aurora kinases, such as Aurora A, mediates resistance to such anti-cancer agents and the resistance of a cancer cell may be reduced by inhibiting aurora kinases and/or predicted by measuring the expression or activity of aurora kinases within the cell.

IT 331771-20-1 823807-50-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (aurora kinase inhibitors for reducing resistance of cancer cells to mitotic spindle assembly inhibitors)

RN 331771-20-1 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino)phenyl]- (CA INDEX NAME)




RN 823807-50-7 CAPLUS

CN Benzenepropanoic acid, β -(benzoylamino)- α -hydroxy-,
 (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzyloxy)-
 2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-
 tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl
 ester, (α R, β S)-, mixt. with
 N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-
 quinazolinyl)amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1

CRN 331771-20-1

CMF C29 H31 N5 O4




CM 2

CRN 33069-62-4

CMF C47 H51 N O14

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 20041059178 CAPLUS
 DOCUMENT NUMBER: 142:38270
 TITLE: A preparation of macrocyclic quinazoline derivatives, useful as antiproliferative agents
 INVENTOR(S): Freyne, Eddy Jean Edgard; Perera, Timothy Pietro; Suren; Buijnsters, Peter Jacobus Johannes Antonius; Willems, Marc; Diels, Gaston Stanislas Marcella; Embrechts, Werner Constant Johan; Ten Holte, Peter Janssen Pharmaceutica N.V., Belg.
 PATENT ASSIGNEE(S):
 SOURCE: PCT Int. Appl., 196 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|----------|
| WO 2004105765 | A1 | 20041209 | WO 2004-EP5621 | 20040525 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TR, TN, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2004243487 | A1 | 20041209 | AU 2004-243487 | 20040525 |
| CA 2525214 | A1 | 20041209 | CA 2004-2525214 | 20040525 |
| EP 1633365 | A1 | 20060315 | EP 2004-739341 | 20040525 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR | | | | |
| BR 2004010714 | A | 20060613 | BR 2004-10714 | 20040525 |
| CN 1794996 | A | 20060628 | CN 2004-80014512 | 20040525 |
| JP 2007504276 | T | 20070301 | JP 2006-529915 | 20040525 |
| IN 2005DN05320 | A | 20080104 | IN 2005-DN5320 | 20051121 |

| | | | | |
|------------------------|----|----------|-----------------|------------|
| US 20060247237 | A1 | 20061102 | US 2005-558007 | 20051122 |
| MX 2005012762 | A | 20060213 | MX 2005-12762 | 20051125 |
| NO 200506196 | A | 20051228 | NO 2005-6196 | 20051227 |
| PRIORITY APPLN. INFO.: | | | WO 2003-EP5723 | A 20030527 |
| | | | WO 2003-EP10266 | A 20030915 |
| | | | WO 2003-EP51061 | A 20031218 |
| | | | WO 2004-EP5621 | W 20040525 |

OTHER SOURCE(S): MARPAT 142:38270
GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

- AB The invention relates to a preparation of macrocyclic derivs. of formula I [wherein: Z is O, CH₂, NH, or S; Y is alk(en/yn)yl, alkyl-C(O)NH, C(O)alkyl, or C(O)NH-alkyl, etc.; X1 and X2 are independently selected from a direct bond, O, O-alkyl, CH₂, or ON:CH, etc.; R1 is H, CN, halogen, OH, CHO, or alkyl, etc.; R2 is H, CN, OH, alkylcarbonyl, or aminocarbonyl, etc.; R3 is H or alkyl; R4 is H, OH, aryloxy, alkoxy, or alkenyloxy, etc.], useful as antiproliferative agents. For instance, pyrimidobenzodioxazacyclopentadecine derivative II [kinase activity: pIC50 = 7.8, A431 cell (C5): pIC50 < 6] was prepared via intramol. heterocyclization/etherification of the prepared quinazoline derivative III.
- IT 807640-31-9P 807640-32-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of macrocyclic quinazoline derivs. useful as antiproliferative agents)
- RN 807640-31-9 CAPLUS
- CN Benzamide, N-[3-[(6-(acetyloxy)hexyl]oxy]-4-[(6-(acetyloxy)-7-methoxy-4-quinazolinyl]amino]phenyl]-4-fluoro- (CA INDEX NAME)



RN 807640-32-0 CAPLUS
CN Benzamide, 4-fluoro-N-[3-[(6-hydroxyhexyl)oxy]-4-[(6-hydroxy-7-methoxy-4-

(quinazolinyl)amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2003:339130 CAPLUS
 DOCUMENT NUMBER: 139:143528
 TITLE: Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores
 Ditchfield, Claire; Johnson, Victoria L.; Tighe, Anthony; Ellston, Rebecca; Haworth, Carolyn; Johnson, Trevor; Mortlock, Andrew; Keen, Nicholas; Taylor, Stephen S.
 AUTHOR(S):
 CORPORATE SOURCE: School of Biological Sciences, University of Manchester, Manchester, M13 9PT, UK
 SOURCE: Journal of Cell Biology (2003), 161(2), 267-280
 CODEN: JCLBA3; ISSN: 0021-9525
 PUBLISHER: Rockefeller University Press
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The Aurora/Ipl1 family of protein kinases plays multiple roles in mitosis and cytokinesis. Here, we describe ZM447439, a novel selective Aurora kinase inhibitor. Cells treated with ZM447439 progress through interphase, enter mitosis normally, and assemble bipolar spindles. However, chromosome alignment, segregation, and cytokinesis all fail. Despite the presence of maloriented chromosomes, ZM447439-treated cells exit mitosis with normal kinetics, indicating that the spindle checkpoint is compromised. Indeed, ZM447439 prevents mitotic arrest after exposure to paclitaxel. RNA interference expts. suggest that these phenotypes are due to inhibition of Aurora B, not Aurora A or some other kinase. In the absence of Aurora B function, kinetochore localization of the spindle checkpoint components BubR1, Mad2, and Cenp-E is diminished. Furthermore, inhibition of Aurora B kinase activity prevents the rebinding of BubR1 to metaphase kinetochores after a reduction in centromeric tension. Aurora B kinase activity is also required for phosphorylation of BubR1 on entry


into mitosis. Finally, we show that BubR1 is not only required for spindle checkpoint function, but is also required for chromosome alignment. Together, these results suggest that by targeting checkpoint proteins to kinetochores, Aurora B couples chromosome alignment with anaphase onset.

IT 331771-20-1, ZM 447439

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores)

RN 331771-20-1 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino)phenyl]- (CA INDEX NAME)





REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:228866 CAPLUS
DOCUMENT NUMBER: 134:266317
TITLE: Preparation of quinazolines as aurora 2 kinase inhibitors
INVENTOR(S): Mortlock, Andrew Austen; Keen, Nicholas John; Jung, Frederic Henri; Brewster, Andrew George
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 306 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2001021596 | A1 | 20010329 | WO 2000-GB3580 | 20000918 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, | | | | |

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 CA 2384291 A1 20010329 CA 2000-2384291 20000918
 BR 2000014116 A 20020521 BR 2000-14116 20000918
 EP 1218354 A1 20020703 EP 2000-960840 20000918
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL
 JP 2003509499 T 20030311 JP 2001-524975 20000918
 EE 200200119 A 20030415 EE 2002-119 20000918
 HU 2003000059 A2 20030728 HU 2003-59 20000918
 HU 2003000059 A3 20030828
 BG 106492 A 20030131 BG 2002-106492 20020307
 IN 2002MN00293 A 20050318 IN 2002-MN293 20020308
 ZA 2002002234 A 20030619 ZA 2002-2234 20020319
 NO 2002001399 A 20020430 NO 2002-1399 20020320
 PRIORITY APPLN. INFO.: GB 1999-22154 A 19990921
 GB 1999-22170 A 19990921
 WO 2000-GB3580 W 20000918
 WO 2000-GB9100 A 20000918

OTHER SOURCE(S): MARPAT 134:266317
 GI



AB Title compds. (I) [wherein X = O, S, SO, SO₂, NH, or NR₁₂; R₁₂ = H or alkyl; R₁-R₄ = independently halo, CN, NO₂, alkylsulfanyl, N(OH)R₁₃, or R₁₅X₁; R₁₃ = H or alkyl; X₁ = a direct bond, O, CH₂, OC(O), CO, CO₂, S, SO, SO₂, or (un)substituted NHCO, CONH, SO₂NH, NHSO₂, or NH; R₁₅ = H or (un)substituted hydrocarbyl, heterocycl, or alkoxy; R₅ = NHCO₂R₉, NHCOR₉, NHSO₂R₉, COR₉, CO₂R₉, SOR₉, SO₂R₉, CONR₁₀R₁₁, SONR₁₀R₁₁, or SO₂NR₁₀R₁₁; R₉-R₁₁ = independently H or (un)substituted hydrocarbyl or heterocycl; or R₁₀ and R₁₁ together with the N to which they are attached = (un)substituted heterocycl; R₆ = H or (un)substituted hydrocarbyl or heterocycl; R₇ and R₈ = independently H, halo, alkyl,


(di)alkoxy(methyl), alkanoyl, CF₃, CN, NHY₂, alkenyl, alkynyl, or (un)substituted Ph, PhCH₂, or heterocycl; or a salt, ester, or amide thereof] were prepared as aurora 2 kinase inhibitors for the treatment of proliferative diseases, such as cancer. For example, a 7-step sequence involving (1) alkylation of morpholine with 1-bromo-3-chloropropane (49%), (2) addition of Et vanillate to yield Et 3-methoxy-4-(3-morpholinopropoxy)benzoate (100%), (3) nitration (86%), (4) reduction to the amine using 10% Pd/C (100%), (5) cycloaddn. with formamide to form the quinazoline (68%), (6) chlorination to give 4-chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline (60%), and (7) amination with N-benzoyl-4-aminoaniline (58%) yielded II. The latter inhibited the serine/threonine kinase activity of aurora 2 kinase by 50% at a concentration of 0.0193 μM. In addition, II gave 50% inhibition of MCF-7 cell proliferation at 1.06 μM and reduced BrdU incorporation into cellular DNA by 50% at 0.159–0.209 μM.

IT 331770-21-9P 331771-20-1P

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-substituted quinazoline aurora 2 kinase inhibitors for treatment of cancer and other proliferative diseases)


RN 331770-21-9 CAPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)



RN 331771-20-1 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




IT 331772-11-3P 331772-14-6P 331772-33-9P
 331772-44-2P 331772-45-3P 331772-47-5P
 331772-51-1P 331772-52-2P 331772-53-3P
 331774-61-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of 4-substituted quinazoline aurora 2 kinase inhibitors for treatment of cancer and other proliferative diseases)


RN 331772-11-3 CAPLUS

CN Benzanide, N-[4-[(6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]phenyl]-
 (CA INDEX NAME)




RN 331772-14-6 CAPLUS

CN Benzanide, N-[4-[(6-hydroxy-7-methoxy-4-quinazolinyl)amino]phenyl]-
 (CA INDEX NAME)




RN 331772-33-9 CAPLUS

CN Carbamic acid, [2-[4-[(4-(benzoylamino)phenyl)amino]-6-methoxy-7-quinazolinyl]oxy]ethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 331772-44-2 CAPLUS


CN Benzamide, N-[4-[(7-(2-hydroxyethoxy)-6-methoxy-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331772-45-3 CAPLUS
CN Benzamide, N-[4-[(7-(3-chloropropoxy)-6-methoxy-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331772-47-5 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]-, 1,1-dimethyl ester (CA INDEX NAME)



RN 331772-51-1 CAPLUS
CN Benzamide, N-[4-[(7-(2-aminoethoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]-
(CA INDEX NAME)




RN 331772-52-2 CAPLUS
CN Benzamide, N-[4-[[6-methoxy-7-(3-pyrrolidinyloxy)-4-
quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-53-3 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-(2-pyrrolidinylmethoxy)-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)



RN 331774-61-9 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(3-methylamino)propoxy]-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




| | | | |
|----|--------------|--------------|--------------|
| IT | 331770-24-2P | 331770-25-3P | 331770-26-4P |
| | 331770-38-8P | 331770-39-9P | 331770-40-2P |
| | 331770-41-3P | 331770-42-4P | 331770-47-9P |
| | 331770-50-4P | 331770-51-5P | 331770-52-6P |
| | 331770-53-7P | 331770-54-8P | 331770-55-9P |
| | 331770-56-0P | 331770-57-1P | 331770-67-3P |
| | 331770-68-4P | 331771-08-5P | 331771-09-6P |
| | 331771-10-9P | 331771-11-0P | 331771-12-1P |
| | 331771-13-2P | 331771-14-3P | 331771-15-4P |
| | 331771-16-5P | 331771-17-6P | 331771-22-3P |
| | 331771-29-0P | 331771-30-3P | 331771-32-5P |
| | 331771-33-6P | 331771-34-7P | 331771-39-2P |
| | 331771-44-9P | 331771-45-0P | 331771-48-3P |
| | 331771-49-4P | 331771-50-7P | 331771-53-0P |
| | 331771-54-1P | 331771-61-0P | 331771-63-2P |
| | 331771-64-3P | 331771-65-4P | 331771-66-5P |
| | 331771-68-7P | 331771-71-2P | 331771-75-6P |
| | 331771-76-3P | 331771-77-8P | 331771-78-9P |
| | 331771-79-0P | 331771-82-5P | 331771-83-6P |
| | 331771-84-7P | 331771-85-8P | 331771-88-1P |
| | 331771-97-2P | 331771-98-3P | 331772-02-2P |
| | 331772-03-3P | 331772-04-4P | 331772-07-7P |
| | 331772-09-9P | 331772-10-2P | 331772-12-4P |
| | 331772-13-5P | 331772-15-7P | 331772-16-8P |
| | 331772-17-9P | 331772-18-0P | 331772-19-1P |
| | 331772-20-4P | 331772-21-5P | 331772-22-6P |
| | 331772-23-7P | 331772-24-8P | 331772-25-9P |
| | 331772-26-0P | 331772-27-1P | 331772-28-2P |
| | 331772-29-3P | 331772-30-6P | 331772-31-7P |
| | 331772-32-8P | 331772-34-0P | 331772-35-1P |
| | 331772-36-2P | 331772-37-3P | 331772-38-4P |
| | 331772-39-5P | 331772-40-8P | 331772-41-9P |
| | 331772-42-0P | 331772-43-1P | 331772-46-4P |
| | 331772-48-6P | 331772-49-7P | 331772-50-0P |
| | 331772-54-4P | 331772-55-5P | 331772-56-6P |
| | 331772-57-7P | 331772-58-8P | 331772-59-9P |
| | 331772-60-2P | 331772-61-3P | 331772-62-4P |
| | 331772-63-5P | 331772-64-6P | 331772-65-7P |
| | 331772-66-8P | 331772-67-9P | 331772-68-0P |
| | 331772-69-1P | 331772-70-4P | 331772-71-5P |
| | 331772-72-6P | 331772-73-7P | 331772-74-8P |
| | 331772-75-9P | 331772-76-0P | 331772-77-1P |

331772-78-2P 331772-79-3P 331772-80-6P
 331772-81-7P 331772-82-8P 331772-83-9P
 331772-84-0P 331772-85-1P 331772-86-2P
 331772-87-3P 331772-88-4P 331772-89-5P
 331772-90-8P 331772-91-9P 331772-92-0P
 331772-93-1P 331772-94-2P 331772-95-3P
 331772-96-4P 331772-97-5P 331772-98-6P
 331772-99-7P 331773-00-3P 331773-01-4P
 331773-02-5P 331773-03-6P 331773-04-7P
 331773-05-8P 331773-06-9P 331773-07-0P
 331773-08-1P 331773-09-2P 331773-10-5P
 331773-11-6P 331773-12-7P 331773-13-8P
 331773-14-9P 331773-15-0P 331773-16-1P
 331773-17-2P 331773-18-3P 331773-19-4P
 331773-20-7P 331773-21-8P 331773-22-9P
 331773-23-0P 331773-24-1P 331773-25-2P
 331773-26-3P 331773-27-4P 331773-28-5P
 331773-29-6P 331773-30-9P 331773-31-0P
 331773-32-1P 331773-33-2P 331773-34-3P
 331773-35-4P 331773-36-5P 331773-37-6P
 331773-38-7P 331773-39-8P 331773-40-1P
 331773-41-2P 331773-42-3P 331773-43-4P
 331773-44-5P 331773-45-6P 331773-46-7P
 331773-47-8P 331773-48-9P 331773-49-0P
 331773-50-3P 331773-51-4P 331773-52-5P
 331773-53-6P 331773-54-7P 331773-55-8P
 331773-56-9P 331773-57-0P 331773-58-1P
 331773-59-2P 331773-60-5P 331773-61-6P
 331773-62-7P 331773-63-8P 331773-64-9P
 331773-65-0P 331773-66-1P 331773-67-2P
 331773-68-3P 331773-69-4P 331773-70-7P
 331773-71-8P 331773-72-9P 331773-73-0P
 331773-74-1P 331773-75-2P 331773-76-3P
 331773-77-4P 331773-78-5P 331773-79-6P
 331773-80-9P 331773-81-0P 331773-82-1P
 331773-83-2P 331773-84-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 4-substituted quinazoline aurora 2 kinase inhibitors for treatment of cancer and other proliferative diseases)


RN 331770-24-2 CAPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3,4,5-trimethoxy- (CA INDEX NAME)




RN 331770-25-3 CAPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)aminophenyl]-2,4-difluoro-
(CA INDEX NAME)




RN 331770-26-4 CAPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4,5-dimethoxy-
2-nitro- (CA INDEX NAME)




RN 331770-38-8 CAPLUS

CN Benzamide, 3-cyano-N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331770-39-9 CAPLUS

CN Benzamide, 4-(acetoxy)-N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331770-40-2 CAPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)aminophenyl]-3-methoxy-2-nitro- (CA INDEX NAME)




RN 331770-41-3 CAPLUS


CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-(methylthio)- (CA INDEX NAME)




RN 331770-42-4 CAPLUS
CN Benzamide, 3-(acetyloxy)-N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-
(CA INDEX NAME)




RN 331770-47-9 CAPLUS
CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-fluoro-5-nitro-
(CA INDEX NAME)




RN 331770-50-4 CAPLUS
CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-fluoro-
(CA INDEX NAME)




RN 331770-51-5 CAPLUS
CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2,3-difluoro-
(CA INDEX NAME)




RN 331770-52-6 CAPLUS
CN Benzanide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2,5-difluoro-
(CA INDEX NAME)




RN 331770-53-7 CAPLUS
CN Benzanide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2,3-dimethoxy-
(CA INDEX NAME)



RN 331770-54-8 CAPLUS
CN Benzanide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-hydroxy-3,5-dimethoxy- (CA INDEX NAME)




RN 331770-55-9 CAPLUS
CN Benzoic acid, 2-chloro-4-[[[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 331770-56-0 CAPLUS


CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)aminophenyl]-4-(methylsulfonyl)-3-nitro- (CA INDEX NAME)

PAGE 1-A







RN 331770-57-1 CAPLUS
CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-methoxy-3-nitro- (CA INDEX NAME)




RN 331770-67-3 CAPLUS
CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-fluoro- (CA INDEX NAME)




RN 331770-68-4 CAPLUS
CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3,5-dinitro-(CA INDEX NAME)



RN 331771-08-5 CAPLUS
CN Benzamide, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-(CA INDEX NAME)




RN 331771-09-6 CAPLUS
CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-methylphenyl]-(CA INDEX NAME)




RN 331771-10-9 CAPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]-3-methylphenyl]-
(CA INDEX NAME)




RN 331771-11-0 CAPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-methoxyphenyl]-
(CA INDEX NAME)




RN 331771-12-1 CAPLUS

CN Benzamide, N-[2-cyano-4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331771-13-2 CAPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 331771-14-3 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]-2-methylphenyl]- (CA INDEX NAME)




RN 331771-15-4 CAPLUS

CN Benzamide, N-[2-cyano-4-[(6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331771-16-5 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(3-(4-morpholinyl)propoxy)-4-quinazolinyl]amino)-2-methylphenyl]- (CA INDEX NAME)




RN 331771-17-6 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(3-(4-morpholinyl)propoxy)-4-quinazolinyl]amino)-2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 331771-22-3 CAPLUS

CN Benzanide, 2-chloro-N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]-5-nitro- (CA INDEX NAME)



RN 331771-29-0 CAPLUS


CN Benzanide, 2,4-difluoro-N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)



RN 331771-30-3 CAPLUS


CN Benzamide, N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-4-(methylsulfonyl)-3-nitro- (CA INDEX NAME)

PAGE 1-A






RN 331771-32-5 CAPLUS
 CN Benzamide, 2-fluoro-N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]-5-nitro- (CA INDEX NAME)




RN 331771-33-6 CAPLUS
 CN Benzamide, 3-methoxy-N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]-2-nitro- (CA INDEX NAME)




RN 331771-34-7 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-2-(methylthio)- (CA INDEX NAME)




RN 331771-39-2 CAPLUS

CN Benzamide, 4-methoxy-N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-3-nitro- (CA INDEX NAME)




RN 331771-44-9 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-2,4-dinitro- (CA INDEX NAME)




RN 331771-45-0 CAPLUS

CN Benzamide, 3-(acetylxy)-N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331771-48-3 CAPLUS

CN Benzamide, 2-methoxy-N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331771-49-4 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]-3-nitro- (CA INDEX NAME)




RN 331771-50-7 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]-4-nitro- (CA INDEX NAME)




RN 331771-53-0 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-4-methyl-3-nitro- (CA INDEX NAME)




RN 331771-54-1 CAPLUS

CN Benzamide, 4-fluoro-N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]-3-nitro- (CA INDEX NAME)




RN 331771-61-0 CAPLUS

CN Benzamide, 3-cyano-N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331771-63-2 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 331771-64-3 CAPLUS

CN Benzamide, 3-chloro-4-fluoro-N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331771-65-4 CAPLUS

CN Benzamide, 4-fluoro-N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 331771-66-5 CAPLUS

CN Benzamide, 4-fluoro-N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331771-68-7 CAPLUS

CN Benzamide, 4-methoxy-N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331771-71-2 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]-2-nitro- (CA INDEX NAME)




RN 331771-75-6 CAPLUS


CN Benzamide, N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]-3-methyl- (CA INDEX NAME)



RN 331771-76-7 CAPLUS
CN Benzamide, 2-chloro-N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331771-77-8 CAPLUS
CN Benzamide, 2-fluoro-N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331771-78-9 CAPLUS

CN Benzamide, 2,5-dichloro-N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331771-79-0 CAPLUS

CN Benzamide, 3-fluoro-N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331771-82-5 CAPLUS

CN Benzamide, N-[4-([6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino)phenyl]-2-methyl-3-nitro- (CA INDEX NAME)




RN 331771-83-6 CAPLUS


CN Benzamide, 3-chloro-N-[4-([6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino)phenyl]- (CA INDEX NAME)



RN 331771-84-7 CAPLUS
CN Benzanide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331771-85-8 CAPLUS
CN Benzanide, 2-chloro-N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-5-nitro- (CA INDEX NAME)




RN 331771-88-1 CAPLUS

CN Benzamide, 4-methoxy-N-[4-[(6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl)amino]phenyl]-3-nitro- (CA INDEX NAME)




RN 331771-97-2 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl)amino]phenyl]-2,4-dinitro- (CA INDEX NAME)




RN 331771-98-3 CAPLUS

CN Benzamide, 2,4-difluoro-N-[4-[(6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-02-2 CAPLUS

CN Benzamide, 2-fluoro-N-[4-[(6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-5-nitro- (CA INDEX NAME)




RN 331772-03-3 CAPLUS

CN Benzamide, 3-methoxy-N-[4-[(6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl)amino]phenyl]-2-nitro- (CA INDEX NAME)




RN 331772-04-4 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl)amino]phenyl]-2-(methylothio)- (CA INDEX NAME)




RN 331772-07-7 CAPLUS

CN Benzamide, 3-(acetyloxy)-N-[4-[(6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331772-09-9 CAPLUS

CN Benzamide, N-[4-[(6-(acetyloxy)-7-methoxy-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331772-10-2 CAPLUS

CN Benzamide, N-[4-[(6,7-bis(2-methoxyethoxy)-4-quinazolinyl]amino]phenyl]-
(CA INDEX NAME)




RN 331772-12-4 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]phenyl]-
(CA INDEX NAME)




RN 331772-13-5 CAPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-2-(4-morpholinyl)-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331772-15-7 CAPLUS

CN Benzamide, N-[4-[(7-hydroxy-6-methoxy-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331772-16-8 CAPLUS

CN Benzamide, N-[4-[(7-methoxy-6-(2-(4-morpholinyl)ethoxy)-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-17-9 CAPLUS

CN Benzamide, N-[4-[(7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-18-0 CAPLUS

CN Benzamide, N-[4-[(6-[(3-(1,1-dioxido-4-thiomorpholinyl)propoxy)-7-methoxy-4-quinazolinyl]amino)phenyl]- (CA INDEX NAME)




RN 331772-19-1 CAPLUS

CN Benzamide, N-[4-[(7-methoxy-6-[3-(methylsulfonyl)propoxy)-4-quinazolinyl]amino)phenyl]- (CA INDEX NAME)




RN 331772-20-4 CAPLUS

CN Benzamide, N-[4-[(7-methoxy-6-[(2-(1H-1,2,4-triazol-1-yl)ethoxy]-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331772-21-5 CAPLUS


CN Benzamide, N-[4-[(6-[(2-(dimethylamino)ethoxy]-7-methoxy-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)



RN 331772-22-6 CAPLUS
CN Benzamide, N-[4-[(7-methoxy-6-(3-pyridinylmethoxy)-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-23-7 CAPLUS
CN Benzamide, N-[4-[(7-methoxy-6-(2-methoxyethoxy)-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-24-8 CAPLUS

CN Benzamide, N-[4-[(6-[(dimethylamino)propoxy]-7-methoxy-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331772-25-9 CAPLUS

CN Benzamide, N-[4-[(7-methoxy-6-(phenylmethoxy)-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331772-26-0 CAPLUS

CN Benzamide, N-[4-[(6-(2-hydroxyethoxy)-7-methoxy-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331772-27-1 CAPLUS

CN Benzamide, N-[4-[[7-[3-(1,1-dioxido-4-thiomorpholinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-28-2 CAPLUS

CN Benzamide, N-[4-[(7-[(3-(dimethylamino)propoxy)-6-methoxy-4-quinazolinyl]amino)phenyl]- (CA INDEX NAME)




RN 331772-29-3 CAPLUS


CN Benzamide, N-[4-[(6-methoxy-7-[2-(4-morpholinyl)ethoxy]-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)



RN 331772-30-6 CAPLUS
CN Benzamide, N-[4-[(7-[(dimethylamino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-31-7 CAPLUS
CN Benzamide, N-[4-[(6-methoxy-7-[(2-(1H-1,2,4-triazol-1-yl)ethoxy]-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331772-32-8 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-(3-(methylsulfonyl)propoxy)-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-34-0 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-(3-pyridinylmethoxy)-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-35-1 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-(2-methoxyethoxy)-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331772-36-2 CAPLUS

CN Benzamide, N-[4-[(7-(acetyloxy)-6-methoxy-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331772-37-3 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-((3,4,5-trifluorophenyl)methoxy)-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)



RN 331772-38-4 CAPLUS


CN Benzamide, N-[4-[(6-methoxy-7-[(3-(2,3-dihydro-1H-pyrrol-1-yl)propoxy]-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)



RN 331772-39-5 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(2Z)-4-(1-pyrrolidinyl)-2-buten-1-yl]oxy)-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 331772-40-8 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(2E)-4-(1-pyrrolidinyl)-2-buten-1-yl]oxy)-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 331772-41-9 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(2Z)-4-(1-piperidinyl)-2-buten-1-yl]oxy)-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 331772-42-0 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(2E)-4-(4-morpholinyl)-2-buten-1-yl]oxy)-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 331772-43-1 CAPLUS


CN Benzamide, N-[4-[(6-methoxy-7-[(2E)-4-(4-methyl-1-piperazinyl)-2-buten-1-yl]oxy)-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 331772-46-4 CAPLUS
CN Benzamide, N-[4-[(6-methoxy-7-[(2S)-2-oxiranylmethoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 331772-48-6 CAPLUS
CN Benzamide, N-[4-[(6-methoxy-7-[(1-(1-methylethyl)-3-azetidinyl]oxy)-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-49-7 CAPLUS
CN Benzamide, N-[4-[(6-methoxy-7-[(2R)-2-oxiranylmethoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 331772-50-0 CAPLUS

CN Benzanide, N-[4-[(6-methoxy-7-[2-(2,2,2-trifluoroethoxy)ethoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-54-4 CAPLUS


CN Benzanide, N-[4-[(6-methoxy-7-(4-piperidinylmethoxy)-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-55-5 CAPLUS
CN Benzamide, N-[4-[(6-methoxy-7-[(1-methyl-2-pyrrolidinyl)methoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)



RN 331772-56-6 CAPLUS
CN Benzamide, N-[4-[(6-methoxy-7-[(1-methyl-3-pyrrolidinyl)methoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-57-7 CAPLUS
CN Benzamide, N-[4-[(6-methoxy-7-[(1-methyl-3-pyrrolidinyl)oxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-58-8 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(3-[(2-methoxyethyl)methylamino]propoxy)-4-quinazolinyl]amino)phenyl]- (CA INDEX NAME)




RN 331772-59-9 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(3-(acetyl methylamino)propoxy)-6-methoxy-4-quinazolinyl]amino)phenyl]- (CA INDEX NAME)




RN 331772-60-2 CAPLUS

CN Benzamide, N-[4-[[7-[3-[(dimethylamino)carbonyl]methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)




RN 331772-61-3 CAPLUS

CN Benzamide, N-[4-[[7-[1-(2-hydroxyethyl)-3-pyrrolidinyl]oxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)




RN 331772-62-4 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(1-(2-methoxyethyl)-3-pyrrolidinyl]oxy)-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-63-5 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(1-(cyanomethyl)-3-pyrrolidinyl]oxy)-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-64-6 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(1-(2-methoxyethyl)-4-piperidinyl]oxy)-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-65-7 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(1-(cyanomethyl)-4-piperidinyl]oxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-66-8 CAPLUS

CN Benzamide, N-[4-[(7-[(1-(cyclopropylmethyl)-2-pyrrolidinyl]methoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-67-9 CAPLUS

CN Benzamide, N-[4-[(7-[(1-(cyclobutylmethyl)-2-pyrrolidinyl]methoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-68-0 CAPLUS

CN Benzamide, N-[4-[(7-[(1-(2-hydroxyethyl)-2-pyrrolidinyl]methoxy]-6-methoxy-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331772-69-1 CAPLUS

CN Benzamide, N-[4-[(7-[(1-[2-(ethylthio)ethyl]-2-pyrrolidinyl)methoxy]-6-methoxy-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331772-70-4 CAPLUS

CN Benzanide, N-[4-[[7-[(1-(cyclopropylmethyl)-4-piperidinyl)methoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-71-5 CAPLUS

CN Benzanide, N-[4-[[7-[(1-(2-hydroxyethyl)-4-piperidinyl)methoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-72-6 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(1-(2-methoxyethyl)-4-piperidinyl)methoxy]-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331772-73-7 CAPLUS

CN Benzamide, N-[4-[[7-[(1-(cyanomethyl)-4-piperidinyl)methoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-74-8 CAPLUS

CN Benzamide, N-[4-{[7-[(4,5-dihydro-1H-imidazol-2-yl)methoxy]-6-methoxy-4-quinazolinyl]amino}phenyl]- (CA INDEX NAME)




RN 331772-75-9 CAPLUS

CN Benzamide, N-[4-{[6-methoxy-7-[(2-thienylmethyl)amino]ethoxy]-4-quinazolinyl}amino]benzamide (CA INDEX NAME)




RN 331772-76-0 CAPLUS

CN Benzamide, N-[4-[(7-[(2-[(acetylamino)ethyl]amino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-77-1 CAPLUS

CN Benzamide, N-[4-[(7-[(2-[(bis(1-methylethyl)amino)ethyl]amino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)



RN 331772-78-2 CAPLUS


CN Benzamide, N-[4-[(6-methoxy-7-[(2-[(2-(methylthio)ethyl)amino]ethoxy)-4-quinazolinyl]amino)phenyl]- (CA INDEX NAME)



RN 331772-79-3 CAPLUS


CN Benzamide, N-[4-[(7-[(2-[(1S)-2-amino-1-methyl-2-oxoethyl]amino]ethoxy)-6-methoxy-4-quinazolinyl]amino)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 331772-80-6 CAPLUS

CN Benzamide, N-[4-[(7-[(2-(cyclopropylamino)ethoxy]-6-methoxy-4-quinazolinyl]amino)phenyl]- (CA INDEX NAME)




RN 331772-81-7 CAPLUS


CN Benzamide, N-[4-[(7-[(2-[(cyclopropylmethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino)phenyl]- (CA INDEX NAME)




RN 331772-82-8 CAPLUS
CN Benzanide, N-[4-[[7-[2-(cyclobutylamino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)



RN 331772-83-9 CAPLUS
CN Benzanide, N-[4-[[7-[2-(cyclopentylamino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-84-0 CAPLUS
CN Benzanide, N-[4-[[7-[2-[[3-(1H-imidazol-1-yl)propyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-85-1 CAPLUS

CN Benzamide, N-[4-[(7-[(cyclohexylamino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-86-2 CAPLUS

CN Benzamide, N-[4-[(7-[(4-hydroxycyclohexylamino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-87-3 CAPLUS

CN Benzamide, N-[4-[(7-[(2-[(cyclohexylmethyl)amino]ethoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-88-4 CAPLUS

CN Benzamide, N-[4-[(7-[(2-[(2-hydroxy-1-(hydroxymethyl)-1-methyl-ethyl]amino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-89-5 CAPLUS

CN Benzamide, N-[4-[[7-[2-[(2-hydroxy-1,1-bis(hydroxymethyl)ethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)



RN 331772-90-8 CAPLUS


CN Benzamide, N-[4-[[7-[2-[(1,1-bis(hydroxymethyl)propyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)



RN 331772-91-9 CAPLUS


CN Benzanide, N-[4-[[7-[2-[[1S]-1-(hydroxymethyl)-3-methylbutyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 331772-92-0 CAPLUS

CN Benzanide, N-[4-[[7-[2-[[1-ethyl-2-pyrrolidinyl]methyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)




RN 331772-93-1 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[2-[(3-(2-oxo-1-pyrrolidinyl)propyl]amino)ethoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-94-2 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[2-[(4-tetrahydro-2-furanyl)methyl]amino)ethoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-95-3 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-[(4-[(benzoylamino)phenyl]amino)-6-methoxy-7-quinazolinyl]oxy]ethyl- (CA INDEX NAME)




RN 331772-96-4 CAPLUS


CN Benzamide, N-[(4-[(6-methoxy-7-[(2-[(4-[(benzoylamino)phenyl]amino)-6-methoxy-7-quinazolinyl]ethoxy)methyl]morpholinyl)methyl]phenyl]- (CA INDEX NAME)



RN 331772-97-5 CAPLUS
CN Benzamide, N-[4-[(6-methoxy-7-[(2-[(3-(4-morpholinyl)propyl]amino)ethoxy]-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331772-98-6 CAPLUS
CN Benzamide, N-[4-[(6-methoxy-7-[(2-[(2-piperidinyl)ethyl]amino)ethoxy]-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331772-99-7 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(2-[(1-pyrrolidinyl)ethyl]amino]ethoxy)-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-00-3 CAPLUS

CN Benzamide, N-[4-[(7-[(2-hydroxy-1,1-dimethylpentyl)amino]ethoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-01-4 CAPLUS

CN Benzamide, N-[4-[[7-[2-[(2-hydroxy-1,1-dimethylethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-02-5 CAPLUS

CN Benzamide, N-[4-[[7-[2-[(3-hydroxy-1,1-dimethylpropyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-03-6 CAPLUS

CN Benzanide, N-[4-[(6-methoxy-7-[(2-[(1-methylethyl)amino]ethoxy)-4-quinazolinyl]amino)phenyl]- (CA INDEX NAME)




RN 331773-04-7 CAPLUS

CN Benzanide, N-[4-[(7-[(2-[(1-methylethyl)amino]ethoxy)-6-methoxy-4-quinazolinyl]amino)phenyl]- (CA INDEX NAME)




RN 331773-05-8 CAPLUS

CN Benzamide, N-[4-{[7-{[2-{[(1-hydroxymethyl)propyl]amino}ethoxy]-6-methoxy-4-quinazolinyl]amino}phenyl]- (CA INDEX NAME)




RN 331773-06-9 CAPLUS

CN Benzamide, N-[4-{[7-{[2-{[(2,3-dihydroxypropyl)amino}ethoxy]-6-methoxy-4-quinazolinyl]amino}phenyl]- (CA INDEX NAME)




RN 331773-07-0 CAPLUS

CN Benzamide, N-[4-[[7-[[2-(dimethylamino)ethyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)




RN 331773-08-1 CAPLUS

CN Benzamide, N-[4-[[7-[[2-(diethylamino)ethyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)




RN 331773-09-2 CAPLUS

CN Benzamide, N-[4-[(2-methoxyethyl)amino]ethoxy]-4-quinazolinylbenzamide (CA INDEX NAME)




RN 331773-10-5 CAPLUS

CN Benzamide, N-[4-[[2-[(2-hydroxyethoxy)ethyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]benzamide (CA INDEX NAME)




RN 331773-11-6 CAPLUS

CN Benzamide, N-[4-[(7-[(2-hydroxyethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)




RN 331773-12-7 CAPLUS

CN Benzamide, N-[4-[(7-[(2-mercaptoproethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)




RN 331773-13-8 CAPLUS

CN Benzamide, N-[4-[(7-[(2-[(ethylthio)ethyl]amino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-14-9 CAPLUS

CN Benzamide, N-[4-[(7-[(3-ethoxypropyl)amino]ethoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-15-0 CAPLUS

CN Benzamide, N-[4-[(7-[(3-butoxypropyl)amino]ethoxy)-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)




RN 331773-16-1 CAPLUS

CN Benzamide, N-[4-[(7-[(3-hydroxypropyl)amino]ethoxy)-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)




RN 331773-17-2 CAPLUS

CN Benzamide, N-[4-[(7-[(2-[(5-hydroxypentyl)amino]ethoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-18-3 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(2-methoxy-1-methylethyl)amino]ethoxy)-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-19-4 CAPLUS

CN Benzamide, N-[4-[(7-[(4-hydroxybutyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)




RN 331773-20-7 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(5-methyl-1H-pyrazol-3-yl)amino]ethoxy]quinazolinyl]amino]phenyl- (CA INDEX NAME)




RN 331773-21-8 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[2-[(3-(4-methyl-1-piperazinyl)propyl]amino)ethoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-22-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(2-[(4-[(4-(benzoylamino)phenyl]amino)-6-methoxy-7-quinazolinyl]oxy)ethyl]amino]-, ethyl ester (CA INDEX NAME)




RN 331773-23-0 CAPLUS

CN Benzamide, N-[4-[(7-[(2-(dibutylamino)ethyl]amino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)




RN 331773-24-1 CAPLUS

CN Benzamide, N-[4-[(7-[(2-(dipropylamino)ethyl]amino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)




RN 331773-25-2 CAPLUS

CN Benzamide, N-[4-[(2-[(2-hydroxycyclohexyl)methyl]amino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)




RN 331773-26-3 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[[2-[(2-thienyl)ethyl]amino]ethoxy]-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)




RN 331773-27-4 CAPLUS

CN Benzamide, N-[4-[(7-[(2-[(1-hydroxymethyl)pentyl]amino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-28-5 CAPLUS

CN Benzamide, N-[4-[(7-[(2-[(4-hydroxy-1-(methylthio)butyl]amino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-29-6 CAPLUS

CN Benzanide, N-[4-[[6-methoxy-7-[2-[(2-(1-methyl-2-pyrrolidinyl)ethyl)amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-30-9 CAPLUS

CN Benzanide, N-[4-[[6-methoxy-7-[2-[(5-methyl-2-furanyl)methyl]amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-31-0 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[2-[(tetrahydro-1,1-dioxido-3-thienyl)amino]ethoxy]-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331773-32-1 CAPLUS

CN Benzamide, N-[4-[(7-[2-[(3-hydroxy-2,2-dimethylpropyl)amino]ethoxy]-6-methoxy-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331773-33-2 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(2-[(3-thienylmethyl)amino]ethoxy)-4-quinazolinyl]amino)phenyl]- (CA INDEX NAME)




RN 331773-34-3 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(2-(4-thiomorpholinyloxy)ethoxy)-4-quinazolinyl]amino)phenyl]- (CA INDEX NAME)




RN 331773-35-4 CAPLUS

CN Benzamide, N-[4-[(7-[(2-hydroxyethyl)amino]ethyl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)




RN 331773-36-5 CAPLUS

CN Benzamide, N-[4-[(7-[(2-bis(2-hydroxyethyl)amino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)




RN 331773-37-6 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-(2-(1-piperidinyl)ethoxy)-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-38-7 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(4-pyridinylmethyl)amino]ethoxy)-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-39-8 CAPLUS

CN Benzamide, N-[4-[(2-[2-hydroxy-1-(hydroxymethyl)ethyl]amino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)




RN 331773-40-1 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[2-(methylamino)ethoxy]-4-quinazolinyl]amino)phenyl- (CA INDEX NAME)




RN 331773-41-2 CAPLUS

CN Benzamide, N-[4-[(2-(4-phenylbenzamido)amino)-6-methoxy-4-quinazolinyl]phenyl]- (CA INDEX NAME)




RN 331773-42-3 CAPLUS

CN Benzamide, N-[4-[(2-(diethylamino)ethoxy)-6-methoxy-4-quinazolinyl]phenyl]- (CA INDEX NAME)




RN 331773-43-4 CAPLUS

CN Benzamide, N-[4-[(7-[(2-(hexahydro-1H-azepin-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino)phenyl]- (CA INDEX NAME)




RN 331773-44-5 CAPLUS

CN Benzamide, N-[4-[(7-[(2-[(2-hydroxyethyl)methylamino]ethoxy]-6-methoxy-4-quinazolinyl]amino)phenyl]- (CA INDEX NAME)




RN 331773-45-6 CAPLUS

CN Benzamide, N-[4-[(7-[(2-(2,5-dihydro-1H-pyrrol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino)phenyl]- (CA INDEX NAME)




RN 331773-46-7 CAPLUS

CN Benzamide, N-[4-[(7-[(2-[(2-(dimethylamino)ethyl)methylamino]ethoxy]-6-methoxy-4-quinazolinyl]amino)phenyl]- (CA INDEX NAME)




RN 331773-47-8 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-(2-(4-methyl-1-piperazinyl)ethoxy)-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)



RN 331773-48-9 CAPLUS


CN Benzamide, N-[4-[(7-[(2-(4-cyclopropyl-1-piperazinyl)ethoxy]-6-methoxy-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)



RN 331773-49-0 CAPLUS


CN Benzamide, N-[4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]ethoxy]-6-methoxy-4-quinazolinylamino]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 331773-50-3 CAPLUS

CN Benzamide, N-[4-[(2-[(4-hydroxy-1-piperidinyl)ethoxy]-6-methoxy-4-quinazolinylamino]phenyl]- (CA INDEX NAME)




RN 331773-51-4 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[2-[4-(4-morpholinyl)ethyl]-1-piperazinyl]ethoxy)-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)




RN 331773-52-5 CAPLUS

CN Benzamide, N-[4-[[7-[2-[4-(3-hydroxypropyl)-1-piperazinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)




RN 331773-53-6 CAPLUS

CN Benzamide, N-[4-[(7-[(2-hydroxyethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)




RN 331773-54-7 CAPLUS

CN Benzamide, N-[4-[(7-[(2-(3-hydroxy-1-pyrrolidinyl)ethoxy]-6-methoxy-4-quinazolinyl)amino]phenyl- (CA INDEX NAME)




RN 331773-55-8 CAPLUS

CN Benzamide, N-[4-[(7-[(2-cyanoethyl)methylamino]ethoxy)-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)




RN 331773-56-9 CAPLUS

CN Benzamide, N-[4-[(7-(2-(1,4'-bipiperidinyl)-1'-ylethoxy)-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)




RN 331773-57-0 CAPLUS

CN Benzamide, N-[4-[(7-[(2-(3,5-dimethyl-4-morpholinyl)ethoxy)-6-methoxy-4-quinazolinyl]amino)phenyl]- (CA INDEX NAME)




RN 331773-58-1 CAPLUS

CN Benzamide, N-[4-[(7-[(2-(4-acetyl-1-piperazinyl)ethoxy)-6-methoxy-4-quinazolinyl]amino)phenyl]- (CA INDEX NAME)




RN 331773-59-2 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-{[2-(methyl-2-propenylamino)ethoxy]-4-quinazolinyl}amino)phenyl]- (CA INDEX NAME)




RN 331773-60-5 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-{[2-(2-methyl-1-pyrrolidinyl)ethoxy]-4-quinazolinyl}amino)phenyl]- (CA INDEX NAME)




RN 331773-61-6 CAPLUS

CN Benzamide, N-[4-[(7-[(2-[(1-methylethyl)amino]ethoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-62-7 CAPLUS

CN Benzamide, N-[4-[(7-[(2-[(2-cyanoethyl)ethylamino]ethoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-63-8 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-{[2-(methyl(2-methylpropyl)amino)ethoxy]-4-quinazolinyl}amino)phenyl]- (CA INDEX NAME)




RN 331773-64-9 CAPLUS

CN Benzamide, N-[4-[(7-{[2-(4-ethyl-1-piperazinyl)ethoxy]-6-methoxy-4-quinazolinyl}amino)phenyl]- (CA INDEX NAME)




RN 331773-65-0 CAPLUS

CN Benzamide, N-[4-[(2-[(4-(4-fluorophenyl)-1-piperazinyl]ethoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-66-1 CAPLUS

CN 2-Thiazolidinecarboxylic acid, 3-[(2-[(4-(benzoylamino)phenyl]amino)-6-methoxy-7-quinazolinyl]oxy]ethyl - (CA INDEX NAME)




RN 331773-67-2 CAPLUS

CN Benzamide, N-[4-[(7-[2-[4-(2-hydroxyethyl)-1-piperidinyl]ethoxy]-6-methoxy-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331773-68-3 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-[methyl(3-pyridinylmethyl)amino]ethoxy]-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331773-69-4 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(2-pyridinylmethyl)amino]ethoxy]-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)




RN 331773-70-7 CAPLUS

CN Benzamide, N-[4-[(7-[(2-(2,5-dimethyl-1-pyrrolidinyl)ethoxy]-6-methoxy-4-quinazolinyl)amino]phenyl- (CA INDEX NAME)




RN 331773-71-8 CAPLUS

CN Benzamide, N-[4-[(2-(3,6-dihydro-1(2H)-pyridinyl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-72-9 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[2-(4-methyl-1-piperidinyl)ethoxy]-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331773-73-0 CAPLUS

CN Benzamide, N-[4-[(7-[(2-hydroxyethyl)-1-piperazinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)




RN 331773-74-1 CAPLUS

CN Benzamide, N-[4-[(7-[(2-hydroxyethyl)-1-piperidinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)




RN 331773-75-2 CAPLUS

CN Benzamide, N-[4-[(7-[(2-ethyl-4,5-dihydro-1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-76-3 CAPLUS

CN Benzamide, N-[4-[(7-[(4,5-dihydro-1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)



RN 331773-77-4 CAPLUS


CN Benzamide, N-[4-[(7-[(3-[(2-acetylaminio)ethyl]amino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)



RN 331773-78-5 CAPLUS


CN Benzamide, N-[4-[(7-[(3-[(1S)-2-amino-1-methyl-2-oxoethyl]amino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 331773-79-6 CAPLUS

CN Benzamide, N-[4-[(7-[3-(cyclopropylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-80-9 CAPLUS


CN Benzamide, N-[4-[(7-[3-[(cyclopropylmethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-81-0 CAPLUS
CN Benzamide, N-[4-[[7-[3-(cyclobutylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)



RN 331773-82-1 CAPLUS
CN Benzamide, N-[4-[[7-[3-(cyclopentylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-83-2 CAPLUS
CN Benzamide, N-[4-[[7-[3-[(3-(1H-imidazol-1-yl)propyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)



RN 331773-84-3 CAPLUS

CN Benzamide, N-[4-[(7-[(cyclohexylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




IT 331773-85-4P 331773-86-5P 331773-87-6P
 331773-88-7P 331773-89-8P 331773-90-1P
 331773-91-2P 331773-92-3P 331773-93-4P
 331773-94-5P 331773-95-6P 331773-96-7P
 331773-97-8P 331773-98-9P 331773-99-0P
 331774-00-6P 331774-01-7P 331774-02-8P
 331774-03-9P 331774-04-0P 331774-05-1P
 331774-06-2P 331774-07-3P 331774-08-4P
 331774-09-5P 331774-10-8P 331774-11-9P
 331774-12-0P 331774-13-1P 331774-15-3P
 331774-17-5P 331774-18-6P 331774-19-7P
 331774-20-0P 331774-21-1P 331774-22-2P
 331774-23-3P 331774-24-4P 331774-25-5P
 331774-26-6P 331774-27-7P 331774-28-8P
 331774-29-9P 331774-30-2P 331774-31-3P
 331774-32-4P 331774-33-5P 331774-34-6P
 331774-35-7P 331774-36-8P 331774-37-9P
 331774-38-0P 331774-39-1P 331774-40-4P
 331774-41-5P 331774-42-6P 331774-43-7P

331774-44-8P 331774-45-9P 331774-46-0P
 331774-47-1P 331774-48-2P 331774-49-3P
 331774-50-6P 331774-51-7P 331774-52-8P
 331774-53-9P 331774-54-0P 331774-55-1P
 331774-56-2P 331774-57-3P 331774-58-4P
 331774-59-5P 331774-60-8P 331774-62-0P
 331774-63-1P 331774-64-2P 331774-65-3P
 331774-66-4P 331774-67-5P 331774-68-6P
 331774-69-7P 331774-70-0P 331774-71-1P
 331774-72-2P 331774-73-3P 331774-74-4P
 331774-75-5P 331774-76-6P 331774-77-7P
 331774-78-8P 331774-79-9P 331774-80-2P
 331774-81-3P 331774-82-4P 331774-83-5P
 331774-84-6P 331774-85-7P 331774-86-8P
 331774-87-9P 331774-88-0P 331774-89-1P
 331774-90-4P 331774-91-5P 331774-92-6P
 331774-93-7P 331774-94-8P 331774-95-9P
 331774-96-0P 331774-97-1P 331774-98-2P
 331774-99-3P 331775-00-9P 331775-01-0P
 331775-02-1P 331775-03-2P 331775-04-3P
 331775-05-4P 331775-06-5P 331775-07-6P
 331775-08-7P 331775-09-8P 331775-10-1P
 331775-11-2P 331775-12-3P 331775-13-4P
 331775-14-5P 331775-15-6P 331775-16-7P
 331775-17-8P 331775-18-9P 331775-19-0P
 331775-20-3P 331775-21-4P 331775-22-5P
 331775-23-6P 331775-24-7P 331775-25-8P
 331775-26-9P 331775-27-0P 331775-28-1P
 331775-29-2P 331775-30-5P 331775-31-6P
 331775-32-7P 331775-33-8P 331775-34-9P
 331775-35-0P 331775-36-1P 331775-37-2P
 331775-38-3P 331775-39-4P 331775-40-7P
 331775-41-8P 331775-42-9P 331775-43-0P
 331775-44-1P 331775-45-2P 331775-46-3P
 331810-24-3P 331825-58-2P 331825-60-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 4-substituted quinazoline aurora 2 kinase inhibitors for treatment of cancer and other proliferative diseases)


RN 331773-85-4 CAPLUS

CN Benzamide, N-[4-[(7-[3-[(4-hydroxycyclohexyl)amino]propoxy]-6-methoxy-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331773-86-5 CAPLUS

CN Benzamide, N-[4-[(7-[3-[(cyclohexylmethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-87-6 CAPLUS


CN Benzamide, N-[4-[(7-[3-[(2-hydroxy-1-(hydroxymethyl)-1-methylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)



RN 331773-88-7 CAPLUS
 CN Benzanide, N-[4-[[7-[3-[(2-hydroxy-1,1-bis(hydroxymethyl)ethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-89-8 CAPLUS
 CN Benzanide, N-[4-[[7-[3-[(1,1-bis(hydroxymethyl)propyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-90-1 CAPLUS
 CN Benzamide, N-[4-[[7-[3-[(1S)-1-(hydroxymethyl)-3-methylbutyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 331773-91-2 CAPLUS
 CN Benzamide, N-[4-[[6-methoxy-7-[3-[(1(tetrahydro-2-furanyl)methyl)amino]propoxy]-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)




RN 331773-92-3 CAPLUS

CN 4-Piperidinecarboxamide, 1-[3-[(4-[(benzoylamino)phenyl]amino)-6-methoxy-7-quinazolinyl]oxy]propyl- (CA INDEX NAME)




RN 331773-93-4 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(3-[(2-(4-morpholinyl)ethyl]amino)propoxy]-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331773-94-5 CAPLUS

CN Benzamide, N-[4-[[7-[3-[(2-hydroxy-1,1-dimethylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-95-6 CAPLUS

CN Benzamide, N-[4-[[7-[3-[(3-hydroxy-1,1-dimethylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-96-7 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(3-[(1-methylpropyl)amino]propoxy]-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331773-97-8 CAPLUS


CN Benzamide, N-[4-[(7-[(3-[(2-hydroxy-1-methylpropyl)amino]propoxy)-6-methoxy-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)



RN 331773-98-9 CAPLUS
 CN Benzamide, N-[4-[(7-[3-[(1-hydroxymethyl)propyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-99-0 CAPLUS
 CN Benzamide, N-[4-[(7-[3-[(2,3-dihydroxypropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331774-00-6 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-[(2-methoxyethyl)amino]propoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331774-01-7 CAPLUS

CN Benzamide, N-[4-[[7-[3-[[2-(2-hydroxyethoxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331774-02-8 CAPLUS

CN Benzamide, N-[4-[(7-[(2-mercaptoethyl)amino]propoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331774-03-9 CAPLUS

CN Benzamide, N-[4-[(7-[[3-[[2-(ethylthio)ethyl]amino]propoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331774-04-0 CAPLUS

CN Benzamide, N-[4-[(7-[(3-(diethylamino)propyl)amino]propoxy)-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)




RN 331774-05-1 CAPLUS

CN Benzamide, N-[4-[(7-[(3-ethoxypropyl)amino]propoxy)-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)




RN 331774-06-2 CAPLUS

CN Benzamide, N-[4-[(7-[(3-hydroxypropyl)amino]propoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331774-07-3 CAPLUS

CN Benzamide, N-[4-[(7-[(5-hydroxypentyl)amino]propoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331774-08-4 CAPLUS
 CN 2-Pyrrolidinecarboxamide, 1-[3-[(4-[(4-(benzoylamino)phenyl]amino)-6-methoxy-7-quinazolinyl]oxyl]propyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.




RN 331774-09-5 CAPLUS
 CN Benamide, N-[4-[(6-methoxy-7-[3-[(5-methyl-1H-pyrazol-3-yl)amino]propoxy]-4-quinazolinyl)aminophenyl]- (CA INDEX NAME)




RN 331774-10-8 CAPLUS
 CN Benzamide, N-[4-[[7-[3-[(2-hydroxycyclohexyl)methyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)



RN 331774-11-9 CAPLUS
 CN Benzamide, N-[4-[[7-[3-[(1-hydroxyhexyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)




RN 331774-12-0 CAPLUS
 CN Benzamide, N-[4-[[6-methoxy-7-[3-[(5-methyl-2-furanyl)methyl]amino]propoxy]-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)




RN 331774-13-1 CAPLUS

CN Benzamide, N-[4-[(7-[(3-hydroxy-2,2-dimethylpropyl)amino]propoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331774-15-3 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(3-thienylmethyl)amino]propoxy)-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331774-17-5 CAPLUS

CN Benzamide, N-[4-[(7-[(3-[(2-hydroxyethyl)amino]propoxy)-6-methoxy-4-quinazolinyl]amino)phenyl]- (CA INDEX NAME)




RN 331774-18-6 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(3-[(2-thienylmethyl)amino]propoxy)-4-quinazolinyl]amino)phenyl]- (CA INDEX NAME)




RN 331774-19-7 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-{3-(1-piperidinyl)propoxy}-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331774-20-0 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-{3-(1-pyrrolidinyl)propoxy}-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331774-21-1 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331774-22-2 CAPLUS

CN Benzamide, N-[4-[(7-[(diethylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331774-23-3 CAPLUS

CN Benzamide, N-[4-[(7-[(2-hydroxyethyl)amino]propoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331774-24-4 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(3-methyl-1-methyl-3-pyrrolidinyl)amino]propoxy)-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331774-25-5 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-[methyl[2-(methylamino)-2-oxoethyl]amino]propoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331774-26-6 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-(2-oxo-1-piperazinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331774-27-7 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-[(tetrahydro-4-hydroxy-3-furanyl)amino]propoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331774-28-8 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-[(4-methyl-1-piperidinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331774-29-9 CAPLUS

CN Benzamide, N-[4-[(7-[(3,5-dimethyl-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331774-30-2 CAPLUS

CN Pentitol, 1,5-anhydro-2-[[3-[[4-[(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]methylamino]-2,4-dideoxy-3-C-methyl- (9CI) (CA INDEX NAME)



RN 331774-31-3 CAPLUS


CN Benzamide, N-[4-[(17-[3-(2-cyclopentenylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)



RN 331774-32-4 CAPLUS

CN Benzamide, N-[4-[(17-[3-[(2S,4R)-4-hydroxy-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-33-5 CAPLUS


CN threo-Pentitol, 1,5-anhydro-3-[(3-[(4-[(4-(benzoylamino)phenyl]amino)-6-methoxy-7-quinazolinyl]oxy)propyl)methylamino]-2,3-dideoxy- (CA INDEX NAME)

Relative stereochemistry.




RN 331774-34-6 CAPLUS

CN Benzamide, N-[4-[(7-[(3-[(cyclobutylmethyl)methylamino]propoxy)-6-methoxy-4-quinazolinyl]amino)phenyl]- (CA INDEX NAME)




RN 331774-35-7 CAPLUS

CN Benzamide, N-[4-[(7-[(3-hydroxy-1-azetidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331774-36-8 CAPLUS

CN Benzamide, N-[4-[(7-[(2-cyanoethyl)methylamino]propoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331774-37-9 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-[methyl[2-(4-morpholinyl)ethyl]amino]propoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331774-38-0 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-[4-(2-methoxyethyl)-1-piperazinyl]propoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331774-39-1 CAPLUS

CN Benzamide, N-[4-[(7-[(3,5-dimethyl-4-morpholinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331774-40-4 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(3-(4-thiomorpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331774-41-5 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-(2-methyl-1-piperidinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331774-42-6 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-(2,6-dimethyl-1-piperidinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331774-43-7 CAPLUS

CN Benzamide, N-[4-[(7-[3-[2-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331774-44-8 CAPLUS

CN Benzamide, N-[4-[(7-[3-(3-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331774-45-9 CAPLUS

CN Benzamide, N-[4-[(7-[3-(2,5-dihydro-1H-pyrrol-1-yl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331774-46-0 CAPLUS

CN Benzamide, N-[4-[(7-[3-[bis(2-methoxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331774-47-1 CAPLUS

CN Benzamide, N-[4-[[7-[3-(4-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331774-48-2 CAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-[4-(1-methylethyl)-1-piperazinyl]propoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331774-49-3 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-[methyl(tetrahydro-2-furanyl)methyl]amino)propoxy]-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)



RN 331774-50-6 CAPLUS


CN Benzamide, N-[4-[(7-[3-(4-acetyl-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl)amino]phenyl- (CA INDEX NAME)



RN 331774-51-7 CAPLUS


CN Benzamide, N-[4-[(7-[(3R)-3-hydroxy-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-52-8 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-[methyl(1-methyl-4-piperidinyl)amino]propoxy]-4-quinazolinyl)amino]phenyl- (CA INDEX NAME)




RN 331774-53-9 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-[4-(1-pyrrolidinyl)-1-piperidinyl]propoxy]-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331774-54-0 CAPLUS

CN Benzamide, N-[4-[(7-[3-(hexahydro-4-methyl-1H-azepin-1-yl)propoxy]-6-methoxy-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)




RN 331774-55-1 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-[(tetrahydro-2,2-dimethyl-2H-pyran-4-yl)aminol]propoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331774-56-2 CAPLUS

CN Benzamide, N-[4-[[7-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)



RN 331774-57-3 CAPLUS


CN Benzamide, N-[4-[(7-[(2-hydroxyethyl)methylamino]propoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)



RN 331774-58-4 CAPLUS


CN Benzamide, N-[4-[(7-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 331774-59-5 CAPLUS


CN Benzanide, N-[4-[(7-[3-[3-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)



RN 331774-60-8 CAPLUS

CN Benzanide, N-[4-[(7-[3-[(2R,5R)-2,5-dimethyl-1-piperazinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 331774-62-0 CAPLUS

CN Benzanide, N-[4-[[7-[(2R)-3-[(2-(dimethylamino)ethyl]amino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-63-1 CAPLUS

CN Benzanide, N-[4-[[7-[(2S)-3-[(2-(diethylamino)ethyl]amino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-64-2 CAPLUS

CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[(2-(2-hydroxyethoxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-65-3 CAPLUS


CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-66-4 CAPLUS
CN Benzamide, N-[4-[(7-[(2R)-3-[(2-(ethylthio)ethyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-67-5 CAPLUS
CN Benzamide, N-[4-[(7-[(2R)-3-[(3-(diethylamino)propyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-68-6 CAPLUS
CN Benzamide, N-[4-[[7-[(2R)-3-[(3-ethoxypropyl)amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-69-7 CAPLUS
CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(3-hydroxypropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 331774-70-0 CAPLUS
CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(5-hydroxypentyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-71-1 CAPLUS

CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[(4-hydroxybutyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-72-2 CAPLUS


CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[(5-methyl-1H-pyrazol-3-yl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-73-3 CAPLUS
CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[(1-hydroxycyclohexyl)methyl]aminopropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-74-4 CAPLUS
CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[(2-(2-thienyl)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 331774-75-5 CAPLUS
CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[(1-(hydroxymethyl)pentyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-76-6 CAPLUS

CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[(2-(1-methyl-2-pyrrolidinyl)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-77-7 CAPLUS

CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[(5-methyl-2-furanyl)methyl]amino]propoxy]-6-methoxy-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-78-8 CAPLUS

CN Benzanide, N-[4-[(7-[(2R)-2-hydroxy-3-[(3-hydroxy-2,2-dimethylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-79-9 CAPLUS


CN Benzanide, N-[4-[(7-[(2S)-2-hydroxy-3-[(3-thienylmethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-80-2 CAPLUS
CN Benamide, N-[4-[(7-[(2S)-3-[(2,3-dihydroxypropyl)amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-81-3 CAPLUS
CN Benamide, N-[4-[(7-[(2S)-3-(cyclobutylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-82-4 CAPLUS
CN Benzamide, N-[4-[(17-[(2S)-3-(cyclopentylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-83-5 CAPLUS
CN Benzamide, N-[4-[(17-[(2S)-2-hydroxy-3-[(3-(1H-imidazol-1-yl)propyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 331774-84-6 CAPLUS
CN Benzamide, N-[4-[(7-[(2R)-3-(cyclohexylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-85-7 CAPLUS

CN Benzamide, N-[4-[(7-[(2R)-3-[(cyclohexylmethyl)amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]aminophenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-86-8 CAPLUS


CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[(2-hydroxy-1-(hydroxymethyl)-1-methylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]aminophenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-87-9 CAPLUS
CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[(2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl] - (CA INDEX NAME)

Absolute stereochemistry.



RN 331774-88-0 CAPLUS
CN Benzamide, N-[4-[[7-((2R)-3-[[1,1-bis(hydroxymethyl)propyl]amino]-2-hydroxypropoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-89-1 CAPLUS

CN Benzamide, N-[4-[(7-[(2R)-3-[(1-ethyl-2-pyrrolidinyl)methyl]amino]-2-hydroxypropoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-90-4 CAPLUS

CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[(tetrahydro-2-furanyl)methyl]amino]propoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-91-5 CAPLUS

CN 4-Piperidinecarboxamide, 1-[(2R)-3-[[4-[(4-(benzoylamino)phenyl)amino]-6-methoxy-7-quinazolinyl]oxy]-2-hydroxypropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-92-6 CAPLUS

CN Benzanide, N-[4-[[7-[(2R)-2-hydroxy-3-[(2-(4-morpholinyl)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-93-7 CAPLUS

CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-94-8 CAPLUS

CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[(3-hydroxy-1,1-dimethylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-95-9 CAPLUS

CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[(1-methylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-96-0 CAPLUS

CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[(2-hydroxy-1-methylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-97-1 CAPLUS

CN Benzamide, N-[4-[(7-[(2R)-3-(cyclopropylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-98-2 CAPLUS

CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[(2-thienylmethyl)amino]propoxy]-6-methoxy-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-99-3 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-3-[(2-(acetylamino)ethyl]amino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-00-9 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(2-(methylthio)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]aminophenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-01-0 CAPLUS

CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(2-(1-piperidinyl)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]aminophenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-02-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2S)-3-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]-2-hydroxypropyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-03-2 CAPLUS

CN Benzanide, N-[4-[(7-[(2S)-2-hydroxy-3-[(1S)-1-(hydroxymethyl)-3-methylbutyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-04-3 CAPLUS

CN Benzamide, N-[4-[(2S)-2-hydroxy-3-[(1R)-1-(hydroxymethyl)propyl]amino]propoxyl]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-05-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2R)-3-[(4-[(benzoylamino)phenyl]amino)-6-methoxy-7-quinazolinyl]oxy]-2-hydroxypropyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-06-5 CAPLUS

CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[(1S)-1-(hydroxymethyl)-3-methylbutyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-07-6 CAPLUS

CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[(1R)-1-(hydroxymethyl)propyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-08-7 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-3-[(2-(dimethylamino)ethyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-09-8 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[(2-(2-hydroxyethoxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-10-0 CAPLUS

CN Benzamide, N-[4-[(7-[(2S)-2-hydroxyethyl]amino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-11-2 CAPLUS

CN Benzamide, N-[4-[(7-[(2S)-3-[(2-ethylthio)ethyl]amino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-12-3 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-3-[(3-(diethylamino)propyl)amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-13-4 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-3-[(3-ethoxypropyl)amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-14-5 CAPLUS


CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[(3-hydroxypropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 331775-15-6 CAPLUS
CN Benzamide, N-[4-[(7-[(2S)-2-hydroxy-3-[(5-hydroxypentyl)amino]propoxy]-6-methoxy-4-quinazolinyl]aminophenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 331775-16-7 CAPLUS
CN Benzamide, N-[4-[(7-[(2S)-2-hydroxy-3-[(4-hydroxybutyl)amino]propoxy]-6-methoxy-4-quinazolinyl]aminophenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-17-8 CAPLUS

CN Benzamide, N-[4-[(17-[(2S)-2-hydroxy-3-[(5-methyl-1H-pyrazol-3-yl)aminol]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-18-9 CAPLUS

CN Benzamide, N-[4-[(17-[(2S)-2-hydroxy-3-[(1-hydroxycyclohexyl)methyl]aminol]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-19-0 CAPLUS

CN Benzamide, N-[4-[(17-[(2S)-2-hydroxy-3-[(2-(2-thienyl)ethyl]aminol]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-20-3 CAPLUS

CN Benzamide, N-[4-[(7-[(2S)-2-hydroxy-3-[(1-(hydroxymethyl)pentyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-21-4 CAPLUS

CN Benzamide, N-[4-[(7-[(2S)-2-hydroxy-3-[(2-(1-methyl-2-pyrrolidinyl)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-22-5 CAPLUS

CN Benzamide, N-[4-[(7-[(2S)-2-hydroxy-3-[(5-methyl-2-furanyl)methyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-23-6 CAPLUS

CN Benzamide, N-[4-[(7-[(2S)-2-hydroxy-3-[(3-hydroxy-2,2-dimethylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-24-7 CAPLUS

CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[(3-thienylmethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-25-8 CAPLUS


CN Benzamide, N-[4-[(7-[(2R)-3-(cyclobutylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 331775-26-9 CAPLUS
CN Benzamide, N-[4-[[7-[(2R)-3-(cyclopentylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 331775-27-0 CAPLUS
CN Benzamide, N-[4-[[7-[(2S)-3-(cyclohexylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 331775-28-1 CAPLUS
CN Benzamide, N-[4-[[7-[(2S)-3-[(cyclohexylmethyl)amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-29-2 CAPLUS

CN Benzamide, N-[4-[(2S)-2-hydroxy-3-[(2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-30-5 CAPLUS

CN Benzamide, N-[4-[(2S)-3-[[1,1-bis(hydroxymethyl)propyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-31-6 CAPLUS

CN Benzamide, N-[4-[(7-[(2S)-3-[(1-ethyl-2-pyrrolidinyl)methyl]amino]-2-hydroxypropoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-32-7 CAPLUS


CN Benzamide, N-[4-[(7-[(2S)-2-hydroxy-3-[(tetrahydro-2-furanyl)methyl]amino]propoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 331775-33-8 CAPLUS
CN 4-Piperidinecarboxamide, 1-[(2S)-3-[[4-[(4-(benzoylamino)phenyl)amino]-6-methoxy-7-quinazolinyl]oxy]-2-hydroxypropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 331775-34-9 CAPLUS
CN Benzanide, N-[4-[[7-[(2S)-2-hydroxy-3-[(2-(4-morpholinyl)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-35-0 CAPLUS

CN Benzamide, N-[4-[(7-[(2S)-2-hydroxy-3-[(2-hydroxy-1,1-dimethylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-36-1 CAPLUS

CN Benzamide, N-[4-[(7-[(2S)-2-hydroxy-3-[(3-hydroxy-1,1-dimethylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-37-2 CAPLUS

CN Benzamide, N-[4-[(7-[(2S)-2-hydroxy-3-[(1-methylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-38-3 CAPLUS

CN Benzamide, N-[4-[(7-[(2S)-2-hydroxy-3-[(2-hydroxy-1-methylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-39-4 CAPLUS

CN Benzamide, N-[4-[(7-[(2S)-3-(cyclopropylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-40-7 CAPLUS

CN Benzamide, N-[4-[(7-[(2S)-2-hydroxy-3-[(2-thienylmethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-41-8 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-3-[(2-(acetylamino)ethyl]amino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-42-9 CAPLUS

CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[(2-(methylthio)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]aminolphenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-43-0 CAPLUS


CN Benzamide, N-[4-[[7-[(2R)-3-[(bis(2-hydroxyethyl)amino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 331775-44-1 CAPLUS

CN Phosphoric acid, 2-[(4-[(4-(benzoylamino)phenyl]amino)-6-methoxy-7-quinazolinyl]oxy]ethyl bis(1,1-dimethylethyl) ester (CA INDEX NAME)




RN 331775-45-2 CAPLUS

CN Phosphoric acid, 2-[(4-[(4-(benzoylamino)phenyl]amino)-6-methoxy-7-quinazolinyl]oxy]ethyl bis(phenylmethyl) ester (CA INDEX NAME)



RN 331775-46-3 CAPLUS


CN Benzanide, N-[4-[(6-methoxy-7-{[2-(phosphonoxy)ethoxy]-4-quinazolinyl}amino)phenyl]- (CA INDEX NAME)



RN 331810-24-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[3-[(4-[(4-(benzoylamino)phenyl)amino]-6-methoxy-7-quinazolinyl]oxylpropyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331825-58-2 CAPLUS

CN Benzamide, N-[4-[(7-[(2S)-2-hydroxy-3-[(4-hydroxycyclohexyl)amino]propoxy]-6-methoxy-4-quinazolinyl]aminophenyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 331825-60-6 CAPLUS

CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[(4-hydroxycyclohexyl)amino]propoxy]-6-methoxy-4-quinazolinyl]aminophenyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 331776-55-7 331776-56-8 331776-57-9,
 4-((4-(N-Benzoyl)amino)anilino)-6-methoxy-7-hydroxyquinazoline
 trifluoroacetate 331776-58-0,
 4-((4-(N-Benzoyl)amino)anilino)-6-methoxy-7-benzyloxyquinazoline
 trifluoroacetate 331776-59-1 331776-60-4
 331776-61-5, 4-((4-(N-Benzoyl)amino)anilino)-6-methoxy-7-(4-
 piperidin oxy)quinazoline 331776-65-9,
 4-((4-(N-Benzoyl)amino)anilino)-6-methoxy-7-(2-bromoethoxy)quinazoline
 331776-69-3 331776-71-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reactant; preparation of 4-substituted quinazoline aurora 2 kinase
 inhibitors for treatment of cancer and other proliferative diseases)
 RN 331776-55-7 CAPLUS
 CN Benzamide, N-[4-[(6-(acetyloxy)-7-methoxy-4-quinazolinyl)amino]phenyl]-,
 hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 331776-56-8 CAPLUS
 CN Benzamide, N-[4-[(6-hydroxy-7-methoxy-4-quinazolinyl)amino]phenyl]-,
 hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 331776-57-9 CAPLUS
CN Benzamide, N-[4-((7-hydroxy-6-methoxy-4-quinazolinyl)amino)phenyl]-,
2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 331772-15-7
CMF C22 H18 N4 O3



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 331776-58-0 CAPLUS
 CN Benzamide, N-[4-[(6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 331772-11-3
 CMF C29 H24 N4 O3




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 331776-59-1 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 331776-60-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[(4-(benzoylamino)phenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 331776-61-5 CAPLUS

CN Benzanide, N-[4-[[6-methoxy-7-(4-piperidinyloxy)-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331776-65-9 CAPLUS

CN Benzamide, N-(4-[{7-(2-bromoethoxy)-6-methoxy-4-quinazolinyl]amino}phenyl)-
(CA INDEX NAME)




RN 331776-69-3 CAPLUS

CN Phosphonic acid, [2-[{4-[{4-(benzoylamino)phenyl]amino}-6-methoxy-7-quinazolinyl]oxy]ethyl]-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)



RN 331776-71-7 CAPLUS

CN Methanesulfonic acid, 1,1,1-trifluoro-,
4-[(4-(benzoylamino)phenyl)amino]-6-methoxy-7-quinazolinyl ester (CA
INDEX NAME)

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:462220 CAPLUS

DOCUMENT NUMBER: 125:114665

ORIGINAL REFERENCE NO.: 125:21523a,21526a

TITLE: Preparation of quinoline and quinazoline protein tyrosine kinase inhibitors

INVENTOR(S): Hudson, Alan Thomas; Vile, Sadie; Barraclough, Paul; Franzmann, Karl Witold; McKeown, Stephen Carl; Page, Martin John

PATENT ASSIGNEE(S): Wellcome Foundation Limited, UK


SOURCE: PCT Int. Appl., 139 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 9609294 | A1 | 19960328 | WO 1995-GB2202 | 19950918 |
| W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM | | | | |
| RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| AU 9534824 | A | 19960409 | AU 1995-34824 | 19950918 |
| ZA 9507853 | A | 19970318 | ZA 1995-7853 | 19950918 |
| EP 782570 | A1 | 19970709 | EP 1995-931351 | 19950918 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| JP 10505600 | T | 19980602 | JP 1995-509740 | 19950918 |
| IN 1995CA01119 | A | 20050304 | IN 1995-CA1119 | 19950918 |
| PRIORITY APPLN. INFO.: | | | | |
| | | | GB 1994-18852 | A 19940919 |
| | | | GB 1995-7788 | A 19950413 |
| | | | GB 1995-10757 | A 19950526 |
| | | | WO 1995-GB2202 | W 19950918 |

OTHER SOURCE(S): MARPAT 125:114665
 GI




AB The title compds. [I; X = N, CH; Y = W(CH₂), (CH₂)W, W; W = O, S(O)m, (un)substituted NH; R1 = NH₂, H, halogen, OH, NO₂, CO₂H, CF₃, CF₃O, ureido, etc.; R4 = H, OH, halogen, alkyl, alkoxy, alkylthio, CN, NO₂, CF₃, etc.; n = 1-3; R5 = H, halogen, CF₃, alkyl, alkoxy; R6 = substituted hydrocarbyl, etc.], which are protein tyrosine kinase inhibitors, are prepared. Thus, 4-chloroquinoline was reacted with 4-methoxyaniline in the presence of HCl, producing 4-(4-phenoxyanilino)quinoline hydrochloride, m.p. 216-218°, which demonstrated a IC₅₀ against p56^{lck} protein tyrosine kinase of 5 μM.

IT 179247-42-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinoline and quinazoline protein tyrosine kinase inhibitors)

RN 179247-42-8 CAPLUS
 CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 14:35:20 ON 09 FEB 2009)

FILE 'REGISTRY' ENTERED AT 14:35:34 ON 09 FEB 2009

L1 STRUCTURE uploaded
 L2 22 S L1
 L3 428 S L1 FULL

FILE 'CAPLUS' ENTERED AT 14:36:06 ON 09 FEB 2009
 L4 21 S L3

=> log y
 COST IN U.S. DOLLARS

FULL ESTIMATED COST

| | SINCE FILE ENTRY | TOTAL SESSION |
|--|------------------|---------------|
|--|------------------|---------------|

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

| | SINCE FILE ENTRY | TOTAL SESSION |
|--|------------------|---------------|
| | -17.22 | -17.22 |

STN INTERNATIONAL LOGOFF AT 14:36:46 ON 09 FEB 2009